#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Machine Prediction
Text=Disturbances across whole brain networks during reward anticipation in an abstinent addiction population Graphical abstract Network based statistics (NBS) analyses detected a graph sub-network comprising 153 edges between 59 nodes of the connectome where the ADD group demonstrated significantly less connectivity compared with the CON group.
1-1	0-12	Disturbances	_
1-2	13-19	across	_
1-3	20-25	whole	_
1-4	26-31	brain	_
1-5	32-40	networks	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-6	41-47	during	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-7	48-54	reward	_
1-8	55-67	anticipation	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-9	68-70	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-10	71-73	an	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-11	74-83	abstinent	_
1-12	84-93	addiction	_
1-13	94-104	population	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-14	105-114	Graphical	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-15	115-123	abstract	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	124-131	Network	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	132-137	based	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	138-148	statistics	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	149-150	(	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-20	150-153	NBS	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-21	153-154	)	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-22	155-163	analyses	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-23	164-172	detected	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-24	173-174	a	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-25	175-180	graph	_
1-26	181-192	sub-network	_
1-27	193-203	comprising	_
1-28	204-207	153	_
1-29	208-213	edges	_
1-30	214-221	between	_
1-31	222-224	59	_
1-32	225-230	nodes	_
1-33	231-233	of	_
1-34	234-237	the	_
1-35	238-248	connectome	_
1-36	249-254	where	_
1-37	255-258	the	_
1-38	259-262	ADD	_
1-39	263-268	group	_
1-40	269-281	demonstrated	_
1-41	282-295	significantly	_
1-42	296-300	less	_
1-43	301-313	connectivity	_
1-44	314-322	compared	_
1-45	323-327	with	_
1-46	328-331	the	_
1-47	332-335	CON	_
1-48	336-341	group	_
1-49	341-342	.	_

Text=These differences in connectivity were mostly intra-hemispheric (55%), the majority (38%) being in the right hemisphere.
2-1	343-348	These	_
2-2	349-360	differences	_
2-3	361-363	in	_
2-4	364-376	connectivity	_
2-5	377-381	were	_
2-6	382-388	mostly	_
2-7	389-406	intra-hemispheric	_
2-8	407-408	(	_
2-9	408-411	55%	_
2-10	411-412	)	_
2-11	412-413	,	_
2-12	414-417	the	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
2-13	418-426	majority	_
2-14	427-428	(	_
2-15	428-431	38%	_
2-16	431-432	)	_
2-17	433-438	being	_
2-18	439-441	in	_
2-19	442-445	the	_
2-20	446-451	right	_
2-21	452-462	hemisphere	_
2-22	462-463	.	_

Text=The anatomical distribution of these connectivity differences between the two groups involved frontal (insula, inferior frontal gyrus, orbitofrontal cortex), limbic-associated (anterior cingulate gyrus, thalamus), and striatal (accumbens, caudate, pallidum) regions.
3-1	464-467	The	_
3-2	468-478	anatomical	_
3-3	479-491	distribution	_
3-4	492-494	of	_
3-5	495-500	these	_
3-6	501-513	connectivity	_
3-7	514-525	differences	_
3-8	526-533	between	_
3-9	534-537	the	_
3-10	538-541	two	_
3-11	542-548	groups	_
3-12	549-557	involved	_
3-13	558-565	frontal	_
3-14	566-567	(	_
3-15	567-573	insula	_
3-16	573-574	,	_
3-17	575-583	inferior	_
3-18	584-591	frontal	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-19	592-597	gyrus	_
3-20	597-598	,	_
3-21	599-612	orbitofrontal	_
3-22	613-619	cortex	_
3-23	619-620	)	_
3-24	620-621	,	_
3-25	622-639	limbic-associated	_
3-26	640-641	(	_
3-27	641-649	anterior	_
3-28	650-659	cingulate	_
3-29	660-665	gyrus	_
3-30	665-666	,	_
3-31	667-675	thalamus	_
3-32	675-676	)	_
3-33	676-677	,	_
3-34	678-681	and	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
3-35	682-690	striatal	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
3-36	691-692	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
3-37	692-701	accumbens	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
3-38	701-702	,	_
3-39	703-710	caudate	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-40	710-711	,	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-41	712-720	pallidum	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-42	720-721	)	_
3-43	722-729	regions	_
3-44	729-730	.	_

Text=The connectivity differences reported in this ADD sample indicate alterations between cognitive, striatal and limbic-associated regions during reward anticipation that persist into extended abstinence.
4-1	731-734	The	_
4-2	735-747	connectivity	_
4-3	748-759	differences	_
4-4	760-768	reported	_
4-5	769-771	in	_
4-6	772-776	this	_
4-7	777-780	ADD	_
4-8	781-787	sample	_
4-9	788-796	indicate	_
4-10	797-808	alterations	_
4-11	809-816	between	_
4-12	817-826	cognitive	_
4-13	826-827	,	_
4-14	828-836	striatal	_
4-15	837-840	and	_
4-16	841-858	limbic-associated	_
4-17	859-866	regions	_
4-18	867-873	during	_
4-19	874-880	reward	_
4-20	881-893	anticipation	_
4-21	894-898	that	_
4-22	899-906	persist	_
4-23	907-911	into	_
4-24	912-920	extended	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-25	921-931	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-26	931-932	.	_

Text=Highlights Analytical methods can capture key features of whole brain networks in addiction.
5-1	933-943	Highlights	_
5-2	944-954	Analytical	_
5-3	955-962	methods	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-4	963-966	can	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-5	967-974	capture	_
5-6	975-978	key	_
5-7	979-987	features	_
5-8	988-990	of	_
5-9	991-996	whole	_
5-10	997-1002	brain	_
5-11	1003-1011	networks	_
5-12	1012-1014	in	_
5-13	1015-1024	addiction	_
5-14	1024-1025	.	_

Text=We compared reward network connectivity in addiction (ADD) and control (CON) groups.
6-1	1026-1028	We	_
6-2	1029-1037	compared	_
6-3	1038-1044	reward	_
6-4	1045-1052	network	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-5	1053-1065	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-6	1066-1068	in	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-7	1069-1078	addiction	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-8	1079-1080	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-9	1080-1083	ADD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-10	1083-1084	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-11	1085-1088	and	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-12	1089-1096	control	_
6-13	1097-1098	(	_
6-14	1098-1101	CON	_
6-15	1101-1102	)	_
6-16	1103-1109	groups	_
6-17	1109-1110	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus

Text=The ADD group showed disruptions in global network connectivity.
7-1	1111-1114	The	_
7-2	1115-1118	ADD	_
7-3	1119-1124	group	_
7-4	1125-1131	showed	_
7-5	1132-1143	disruptions	_
7-6	1144-1146	in	_
7-7	1147-1153	global	_
7-8	1154-1161	network	_
7-9	1162-1174	connectivity	_
7-10	1174-1175	.	_

Text=Global network measures may be more sensitive than traditional voxel-wise analyses.
8-1	1176-1182	Global	_
8-2	1183-1190	network	_
8-3	1191-1199	measures	_
8-4	1200-1203	may	_
8-5	1204-1206	be	_
8-6	1207-1211	more	_
8-7	1212-1221	sensitive	_
8-8	1222-1226	than	_
8-9	1227-1238	traditional	_
8-10	1239-1249	voxel-wise	_
8-11	1250-1258	analyses	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
8-12	1258-1259	.	_

Text=The prevalent spatial distribution of abnormalities reported in cognitive fMRI studies in addiction suggests there are extensive disruptions across whole brain networks.
9-1	1260-1263	The	_
9-2	1264-1273	prevalent	_
9-3	1274-1281	spatial	_
9-4	1282-1294	distribution	_
9-5	1295-1297	of	_
9-6	1298-1311	abnormalities	_
9-7	1312-1320	reported	_
9-8	1321-1323	in	_
9-9	1324-1333	cognitive	_
9-10	1334-1338	fMRI	_
9-11	1339-1346	studies	_
9-12	1347-1349	in	_
9-13	1350-1359	addiction	_
9-14	1360-1368	suggests	_
9-15	1369-1374	there	_
9-16	1375-1378	are	_
9-17	1379-1388	extensive	_
9-18	1389-1400	disruptions	_
9-19	1401-1407	across	_
9-20	1408-1413	whole	_
9-21	1414-1419	brain	_
9-22	1420-1428	networks	_
9-23	1428-1429	.	_

Text=Studies using resting state have reported disruptions in network connectivity in addiction, but these studies have not revealed characteristics of network functioning during critical psychological processes that are disrupted in addiction populations.
10-1	1430-1437	Studies	_
10-2	1438-1443	using	_
10-3	1444-1451	resting	_
10-4	1452-1457	state	_
10-5	1458-1462	have	_
10-6	1463-1471	reported	_
10-7	1472-1483	disruptions	_
10-8	1484-1486	in	_
10-9	1487-1494	network	_
10-10	1495-1507	connectivity	_
10-11	1508-1510	in	_
10-12	1511-1520	addiction	_
10-13	1520-1521	,	_
10-14	1522-1525	but	_
10-15	1526-1531	these	_
10-16	1532-1539	studies	_
10-17	1540-1544	have	_
10-18	1545-1548	not	_
10-19	1549-1557	revealed	_
10-20	1558-1573	characteristics	_
10-21	1574-1576	of	_
10-22	1577-1584	network	_
10-23	1585-1596	functioning	_
10-24	1597-1603	during	_
10-25	1604-1612	critical	_
10-26	1613-1626	psychological	_
10-27	1627-1636	processes	_
10-28	1637-1641	that	_
10-29	1642-1645	are	_
10-30	1646-1655	disrupted	_
10-31	1656-1658	in	_
10-32	1659-1668	addiction	_
10-33	1669-1680	populations	_
10-34	1680-1681	.	_

Text=Analytic methods that can capture key features of whole brain networks during psychological processes may be more sensitive in revealing additional and widespread neural disturbances in addiction, that are the provisions for relapse risk, and targets for medication development.
11-1	1682-1690	Analytic	_
11-2	1691-1698	methods	_
11-3	1699-1703	that	_
11-4	1704-1707	can	_
11-5	1708-1715	capture	_
11-6	1716-1719	key	_
11-7	1720-1728	features	_
11-8	1729-1731	of	_
11-9	1732-1737	whole	_
11-10	1738-1743	brain	_
11-11	1744-1752	networks	_
11-12	1753-1759	during	_
11-13	1760-1773	psychological	_
11-14	1774-1783	processes	_
11-15	1784-1787	may	_
11-16	1788-1790	be	_
11-17	1791-1795	more	_
11-18	1796-1805	sensitive	_
11-19	1806-1808	in	_
11-20	1809-1818	revealing	_
11-21	1819-1829	additional	_
11-22	1830-1833	and	_
11-23	1834-1844	widespread	_
11-24	1845-1851	neural	_
11-25	1852-1864	disturbances	_
11-26	1865-1867	in	_
11-27	1868-1877	addiction	_
11-28	1877-1878	,	_
11-29	1879-1883	that	_
11-30	1884-1887	are	_
11-31	1888-1891	the	_
11-32	1892-1902	provisions	_
11-33	1903-1906	for	_
11-34	1907-1914	relapse	_
11-35	1915-1919	risk	_
11-36	1919-1920	,	_
11-37	1921-1924	and	_
11-38	1925-1932	targets	_
11-39	1933-1936	for	_
11-40	1937-1947	medication	_
11-41	1948-1959	development	_
11-42	1959-1960	.	_

Text=The current study compared a substance addiction (ADD; n   =   83) group in extended abstinence with a control (CON; n   =   68) group on functional MRI (voxel-wise activation) and global network (connectivity) measures related to reward anticipation on a monetary incentive delay task.
12-1	1961-1964	The	_
12-2	1965-1972	current	_
12-3	1973-1978	study	_
12-4	1979-1987	compared	_
12-5	1988-1989	a	_
12-6	1990-1999	substance	_
12-7	2000-2009	addiction	_
12-8	2010-2011	(	_
12-9	2011-2014	ADD	_
12-10	2014-2015	;	_
12-11	2016-2017	n	_
12-12	2017-2018	 	_
12-13	2018-2019	=	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-14	2019-2020	 	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-15	2020-2022	83	_
12-16	2022-2023	)	_
12-17	2024-2029	group	_
12-18	2030-2032	in	_
12-19	2033-2041	extended	_
12-20	2042-2052	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-21	2053-2057	with	_
12-22	2058-2059	a	_
12-23	2060-2067	control	_
12-24	2068-2069	(	_
12-25	2069-2072	CON	_
12-26	2072-2073	;	_
12-27	2074-2075	n	_
12-28	2075-2076	 	_
12-29	2076-2077	=	_
12-30	2077-2078	 	_
12-31	2078-2080	68	_
12-32	2080-2081	)	_
12-33	2082-2087	group	_
12-34	2088-2090	on	_
12-35	2091-2101	functional	_
12-36	2102-2105	MRI	_
12-37	2106-2107	(	_
12-38	2107-2117	voxel-wise	_
12-39	2118-2128	activation	_
12-40	2128-2129	)	_
12-41	2130-2133	and	_
12-42	2134-2140	global	_
12-43	2141-2148	network	_
12-44	2149-2150	(	_
12-45	2150-2162	connectivity	_
12-46	2162-2163	)	_
12-47	2164-2172	measures	_
12-48	2173-2180	related	_
12-49	2181-2183	to	_
12-50	2184-2190	reward	_
12-51	2191-2203	anticipation	_
12-52	2204-2206	on	_
12-53	2207-2208	a	_
12-54	2209-2217	monetary	_
12-55	2218-2227	incentive	_
12-56	2228-2233	delay	_
12-57	2234-2238	task	_
12-58	2238-2239	.	_

Text=In the absence of group differences on MID performance, the ADD group showed reduced activation predominantly across temporal and visual regions, but not across the striatum.
13-1	2240-2242	In	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-2	2243-2246	the	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-3	2247-2254	absence	_
13-4	2255-2257	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-5	2258-2263	group	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-6	2264-2275	differences	_
13-7	2276-2278	on	_
13-8	2279-2282	MID	_
13-9	2283-2294	performance	_
13-10	2294-2295	,	_
13-11	2296-2299	the	_
13-12	2300-2303	ADD	_
13-13	2304-2309	group	_
13-14	2310-2316	showed	_
13-15	2317-2324	reduced	_
13-16	2325-2335	activation	_
13-17	2336-2349	predominantly	_
13-18	2350-2356	across	_
13-19	2357-2365	temporal	_
13-20	2366-2369	and	_
13-21	2370-2376	visual	_
13-22	2377-2384	regions	_
13-23	2384-2385	,	_
13-24	2386-2389	but	_
13-25	2390-2393	not	_
13-26	2394-2400	across	_
13-27	2401-2404	the	_
13-28	2405-2413	striatum	_
13-29	2413-2414	.	_

Text=The ADD group also showed disruptions in global network connectivity (lower clustering coefficient and higher characteristic path length), and significantly less connectivity across a sub-network comprising frontal, temporal, limbic and striatal nodes.
14-1	2415-2418	The	_
14-2	2419-2422	ADD	_
14-3	2423-2428	group	_
14-4	2429-2433	also	_
14-5	2434-2440	showed	_
14-6	2441-2452	disruptions	_
14-7	2453-2455	in	_
14-8	2456-2462	global	_
14-9	2463-2470	network	_
14-10	2471-2483	connectivity	_
14-11	2484-2485	(	_
14-12	2485-2490	lower	_
14-13	2491-2501	clustering	_
14-14	2502-2513	coefficient	_
14-15	2514-2517	and	_
14-16	2518-2524	higher	_
14-17	2525-2539	characteristic	_
14-18	2540-2544	path	_
14-19	2545-2551	length	_
14-20	2551-2552	)	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-21	2552-2553	,	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-22	2554-2557	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-23	2558-2571	significantly	_
14-24	2572-2576	less	_
14-25	2577-2589	connectivity	_
14-26	2590-2596	across	_
14-27	2597-2598	a	_
14-28	2599-2610	sub-network	_
14-29	2611-2621	comprising	_
14-30	2622-2629	frontal	_
14-31	2629-2630	,	_
14-32	2631-2639	temporal	_
14-33	2639-2640	,	_
14-34	2641-2647	limbic	_
14-35	2648-2651	and	_
14-36	2652-2660	striatal	_
14-37	2661-2666	nodes	_
14-38	2666-2667	.	_

Text=These results show that an addiction group in extended abstinence exhibit localised disruptions in brain activation, but more extensive disturbances in functional connectivity across whole brain networks.
15-1	2668-2673	These	_
15-2	2674-2681	results	_
15-3	2682-2686	show	_
15-4	2687-2691	that	_
15-5	2692-2694	an	_
15-6	2695-2704	addiction	_
15-7	2705-2710	group	_
15-8	2711-2713	in	_
15-9	2714-2722	extended	_
15-10	2723-2733	abstinence	_
15-11	2734-2741	exhibit	_
15-12	2742-2751	localised	_
15-13	2752-2763	disruptions	_
15-14	2764-2766	in	_
15-15	2767-2772	brain	_
15-16	2773-2783	activation	_
15-17	2783-2784	,	_
15-18	2785-2788	but	_
15-19	2789-2793	more	_
15-20	2794-2803	extensive	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-21	2804-2816	disturbances	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-22	2817-2819	in	_
15-23	2820-2830	functional	_
15-24	2831-2843	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-25	2844-2850	across	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-26	2851-2856	whole	_
15-27	2857-2862	brain	_
15-28	2863-2871	networks	_
15-29	2871-2872	.	_

Text=We propose that measures of global network functioning may be more sensitive in highlighting latent and more widespread neural disruptions during critical psychological processes in addiction and other psychiatric disorders.
16-1	2873-2875	We	_
16-2	2876-2883	propose	_
16-3	2884-2888	that	_
16-4	2889-2897	measures	_
16-5	2898-2900	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
16-6	2901-2907	global	_
16-7	2908-2915	network	_
16-8	2916-2927	functioning	_
16-9	2928-2931	may	_
16-10	2932-2934	be	_
16-11	2935-2939	more	_
16-12	2940-2949	sensitive	_
16-13	2950-2952	in	_
16-14	2953-2965	highlighting	_
16-15	2966-2972	latent	_
16-16	2973-2976	and	_
16-17	2977-2981	more	_
16-18	2982-2992	widespread	_
16-19	2993-2999	neural	_
16-20	3000-3011	disruptions	_
16-21	3012-3018	during	_
16-22	3019-3027	critical	_
16-23	3028-3041	psychological	_
16-24	3042-3051	processes	_
16-25	3052-3054	in	_
16-26	3055-3064	addiction	_
16-27	3065-3068	and	_
16-28	3069-3074	other	_
16-29	3075-3086	psychiatric	_
16-30	3087-3096	disorders	_
16-31	3096-3097	.	_

Text=

Text=

Text=

Text=

Text=

Text=

Text=

Text=Material and methods Participants Sixty-eight control (CON: mean age 39.79   ±   1.22; 18 females, 50 males) and 83 addiction (ADD: mean age 40.05   ±   0.92; 16 females, 67 males) participants completed the current study.
31-1	6090-6098	Material	_
31-2	6099-6102	and	_
31-3	6103-6110	methods	_
31-4	6111-6123	Participants	_
31-5	6124-6135	Sixty-eight	_
31-6	6136-6143	control	_
31-7	6144-6145	(	_
31-8	6145-6148	CON	_
31-9	6148-6149	:	_
31-10	6150-6154	mean	_
31-11	6155-6158	age	_
31-12	6159-6164	39.79	_
31-13	6164-6165	 	_
31-14	6165-6166	±	_
31-15	6166-6167	 	_
31-16	6167-6171	1.22	_
31-17	6171-6172	;	_
31-18	6173-6175	18	_
31-19	6176-6183	females	_
31-20	6183-6184	,	_
31-21	6185-6187	50	_
31-22	6188-6193	males	_
31-23	6193-6194	)	_
31-24	6195-6198	and	_
31-25	6199-6201	83	_
31-26	6202-6211	addiction	_
31-27	6212-6213	(	_
31-28	6213-6216	ADD	_
31-29	6216-6217	:	_
31-30	6218-6222	mean	_
31-31	6223-6226	age	_
31-32	6227-6232	40.05	_
31-33	6232-6233	 	_
31-34	6233-6234	±	_
31-35	6234-6235	 	_
31-36	6235-6239	0.92	_
31-37	6239-6240	;	_
31-38	6241-6243	16	_
31-39	6244-6251	females	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-40	6251-6252	,	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
31-41	6253-6255	67	_
31-42	6256-6261	males	_
31-43	6261-6262	)	_
31-44	6263-6275	participants	_
31-45	6276-6285	completed	_
31-46	6286-6289	the	_
31-47	6290-6297	current	_
31-48	6298-6303	study	_
31-49	6303-6304	.	_

Text=The current dataset was collected as part of a multi-centre study involving three study sites in the United Kingdom (Imperial College London, University of Cambridge and University of Manchester – ICCAM).
32-1	6305-6308	The	_
32-2	6309-6316	current	_
32-3	6317-6324	dataset	_
32-4	6325-6328	was	_
32-5	6329-6338	collected	_
32-6	6339-6341	as	_
32-7	6342-6346	part	_
32-8	6347-6349	of	_
32-9	6350-6351	a	_
32-10	6352-6364	multi-centre	_
32-11	6365-6370	study	_
32-12	6371-6380	involving	_
32-13	6381-6386	three	_
32-14	6387-6392	study	_
32-15	6393-6398	sites	_
32-16	6399-6401	in	_
32-17	6402-6405	the	_
32-18	6406-6412	United	_
32-19	6413-6420	Kingdom	_
32-20	6421-6422	(	_
32-21	6422-6430	Imperial	_
32-22	6431-6438	College	_
32-23	6439-6445	London	_
32-24	6445-6446	,	_
32-25	6447-6457	University	_
32-26	6458-6460	of	_
32-27	6461-6470	Cambridge	_
32-28	6471-6474	and	_
32-29	6475-6485	University	_
32-30	6486-6488	of	_
32-31	6489-6499	Manchester	_
32-32	6500-6501	–	_
32-33	6502-6507	ICCAM	_
32-34	6507-6508	)	_
32-35	6508-6509	.	_

Text=For a more detailed description of the ICCAM Platform, see) and.
33-1	6510-6513	For	_
33-2	6514-6515	a	_
33-3	6516-6520	more	_
33-4	6521-6529	detailed	_
33-5	6530-6541	description	_
33-6	6542-6544	of	_
33-7	6545-6548	the	_
33-8	6549-6554	ICCAM	_
33-9	6555-6563	Platform	_
33-10	6563-6564	,	_
33-11	6565-6568	see	_
33-12	6568-6569	)	_
33-13	6570-6573	and	_
33-14	6573-6574	.	_

Text=Inclusion criteria were individuals who met DSM-IV measures for current or prior substance dependence (e.g., alcohol, cocaine, opiates).
34-1	6575-6584	Inclusion	_
34-2	6585-6593	criteria	_
34-3	6594-6598	were	_
34-4	6599-6610	individuals	_
34-5	6611-6614	who	_
34-6	6615-6618	met	_
34-7	6619-6625	DSM-IV	_
34-8	6626-6634	measures	_
34-9	6635-6638	for	_
34-10	6639-6646	current	_
34-11	6647-6649	or	_
34-12	6650-6655	prior	_
34-13	6656-6665	substance	_
34-14	6666-6676	dependence	_
34-15	6677-6678	(	_
34-16	6678-6681	e.g	_
34-17	6681-6682	.	_
34-18	6682-6683	,	_
34-19	6684-6691	alcohol	_
34-20	6691-6692	,	_
34-21	6693-6700	cocaine	_
34-22	6700-6701	,	_
34-23	6702-6709	opiates	_
34-24	6709-6710	)	_
34-25	6710-6711	.	_

Text=The ADD group consisted of 29 (35%) pure alcohol-dependent, 42 (50%) poly substance-dependent (e.g., alcohol and cocaine, cocaine and opiate) and 12 (15%) mono substance-dependent (e.g., cocaine, opiates) volunteers.
35-1	6712-6715	The	_
35-2	6716-6719	ADD	_
35-3	6720-6725	group	_
35-4	6726-6735	consisted	_
35-5	6736-6738	of	_
35-6	6739-6741	29	_
35-7	6742-6743	(	_
35-8	6743-6746	35%	_
35-9	6746-6747	)	_
35-10	6748-6752	pure	_
35-11	6753-6770	alcohol-dependent	_
35-12	6770-6771	,	_
35-13	6772-6774	42	_
35-14	6775-6776	(	_
35-15	6776-6779	50%	_
35-16	6779-6780	)	_
35-17	6781-6785	poly	_
35-18	6786-6805	substance-dependent	_
35-19	6806-6807	(	_
35-20	6807-6810	e.g	_
35-21	6810-6811	.	_
35-22	6811-6812	,	_
35-23	6813-6820	alcohol	_
35-24	6821-6824	and	_
35-25	6825-6832	cocaine	_
35-26	6832-6833	,	_
35-27	6834-6841	cocaine	_
35-28	6842-6845	and	_
35-29	6846-6852	opiate	_
35-30	6852-6853	)	_
35-31	6854-6857	and	_
35-32	6858-6860	12	_
35-33	6861-6862	(	_
35-34	6862-6865	15%	_
35-35	6865-6866	)	_
35-36	6867-6871	mono	_
35-37	6872-6891	substance-dependent	_
35-38	6892-6893	(	_
35-39	6893-6896	e.g	_
35-40	6896-6897	.	_
35-41	6897-6898	,	_
35-42	6899-6906	cocaine	_
35-43	6906-6907	,	_
35-44	6908-6915	opiates	_
35-45	6915-6916	)	_
35-46	6917-6927	volunteers	_
35-47	6927-6928	.	_

Text=While addiction studies typically recruit volunteers in early abstinence, there was no upper limit in the current study.
36-1	6929-6934	While	_
36-2	6935-6944	addiction	_
36-3	6945-6952	studies	_
36-4	6953-6962	typically	_
36-5	6963-6970	recruit	_
36-6	6971-6981	volunteers	_
36-7	6982-6984	in	_
36-8	6985-6990	early	_
36-9	6991-7001	abstinence	_
36-10	7001-7002	,	_
36-11	7003-7008	there	_
36-12	7009-7012	was	_
36-13	7013-7015	no	_
36-14	7016-7021	upper	_
36-15	7022-7027	limit	_
36-16	7028-7030	in	_
36-17	7031-7034	the	_
36-18	7035-7042	current	_
36-19	7043-7048	study	_
36-20	7048-7049	.	_

Text=The mean abstinence length from alcohol in the current sample was 15.00   ±   3.50   months, while for cocaine and opiates it was 27.99   ±   3.72 and 39.04   ±   7.75   months, respectively.
37-1	7050-7053	The	_
37-2	7054-7058	mean	_
37-3	7059-7069	abstinence	_
37-4	7070-7076	length	_
37-5	7077-7081	from	_
37-6	7082-7089	alcohol	_
37-7	7090-7092	in	_
37-8	7093-7096	the	_
37-9	7097-7104	current	_
37-10	7105-7111	sample	_
37-11	7112-7115	was	_
37-12	7116-7121	15.00	_
37-13	7121-7122	 	_
37-14	7122-7123	±	_
37-15	7123-7124	 	_
37-16	7124-7128	3.50	_
37-17	7128-7129	 	_
37-18	7129-7135	months	_
37-19	7135-7136	,	_
37-20	7137-7142	while	_
37-21	7143-7146	for	_
37-22	7147-7154	cocaine	_
37-23	7155-7158	and	_
37-24	7159-7166	opiates	_
37-25	7167-7169	it	_
37-26	7170-7173	was	_
37-27	7174-7179	27.99	_
37-28	7179-7180	 	_
37-29	7180-7181	±	_
37-30	7181-7182	 	_
37-31	7182-7186	3.72	_
37-32	7187-7190	and	_
37-33	7191-7196	39.04	_
37-34	7196-7197	 	_
37-35	7197-7198	±	_
37-36	7198-7199	 	_
37-37	7199-7203	7.75	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-38	7203-7204	 	_
37-39	7204-7210	months	_
37-40	7210-7211	,	_
37-41	7212-7224	respectively	_
37-42	7224-7225	.	_

Text=Therefore, the current ADD group was made of a heterogenous sample with former substance-dependencies, and with variable levels of substance abstinence at the time of testing.
38-1	7226-7235	Therefore	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-2	7235-7236	,	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-3	7237-7240	the	_
38-4	7241-7248	current	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-5	7249-7252	ADD	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-6	7253-7258	group	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-7	7259-7262	was	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-8	7263-7267	made	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-9	7268-7270	of	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
38-10	7271-7272	a	_
38-11	7273-7285	heterogenous	_
38-12	7286-7292	sample	_
38-13	7293-7297	with	_
38-14	7298-7304	former	_
38-15	7305-7327	substance-dependencies	_
38-16	7327-7328	,	_
38-17	7329-7332	and	_
38-18	7333-7337	with	_
38-19	7338-7346	variable	_
38-20	7347-7353	levels	_
38-21	7354-7356	of	_
38-22	7357-7366	substance	_
38-23	7367-7377	abstinence	_
38-24	7378-7380	at	_
38-25	7381-7384	the	_
38-26	7385-7389	time	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-27	7390-7392	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-28	7393-7400	testing	_
38-29	7400-7401	.	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging

Text=This meant that there was no substance dependence measure that was shared by all members of the ADD group.
39-1	7402-7406	This	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-2	7407-7412	meant	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-3	7413-7417	that	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-4	7418-7423	there	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-5	7424-7427	was	_
39-6	7428-7430	no	_
39-7	7431-7440	substance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
39-8	7441-7451	dependence	_
39-9	7452-7459	measure	_
39-10	7460-7464	that	_
39-11	7465-7468	was	_
39-12	7469-7475	shared	_
39-13	7476-7478	by	_
39-14	7479-7482	all	_
39-15	7483-7490	members	_
39-16	7491-7493	of	_
39-17	7494-7497	the	_
39-18	7498-7501	ADD	_
39-19	7502-7507	group	_
39-20	7507-7508	.	_

Text=The CON group had no previous history of substance abuse, as assessed using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and timeline follow-back.
40-1	7509-7512	The	_
40-2	7513-7516	CON	_
40-3	7517-7522	group	_
40-4	7523-7526	had	_
40-5	7527-7529	no	_
40-6	7530-7538	previous	_
40-7	7539-7546	history	_
40-8	7547-7549	of	_
40-9	7550-7559	substance	_
40-10	7560-7565	abuse	_
40-11	7565-7566	,	_
40-12	7567-7569	as	_
40-13	7570-7578	assessed	_
40-14	7579-7584	using	_
40-15	7585-7588	the	_
40-16	7589-7596	Alcohol	_
40-17	7596-7597	,	_
40-18	7598-7605	Smoking	_
40-19	7606-7609	and	_
40-20	7610-7619	Substance	_
40-21	7620-7631	Involvement	_
40-22	7632-7641	Screening	_
40-23	7642-7646	Test	_
40-24	7647-7648	(	_
40-25	7648-7654	ASSIST	_
40-26	7654-7655	)	_
40-27	7656-7659	and	_
40-28	7660-7668	timeline	_
40-29	7669-7680	follow-back	_
40-30	7680-7681	.	_

Text=All participants were required to provide a negative breath alcohol test and a negative urine sample for various drugs of abuse on the day of testing (screening for the presence of amphetamines, benzodiazepines, cannabinoids, cocaine and opiates).
41-1	7682-7685	All	_
41-2	7686-7698	participants	_
41-3	7699-7703	were	_
41-4	7704-7712	required	_
41-5	7713-7715	to	_
41-6	7716-7723	provide	_
41-7	7724-7725	a	_
41-8	7726-7734	negative	_
41-9	7735-7741	breath	_
41-10	7742-7749	alcohol	_
41-11	7750-7754	test	_
41-12	7755-7758	and	_
41-13	7759-7760	a	_
41-14	7761-7769	negative	_
41-15	7770-7775	urine	_
41-16	7776-7782	sample	_
41-17	7783-7786	for	_
41-18	7787-7794	various	_
41-19	7795-7800	drugs	_
41-20	7801-7803	of	_
41-21	7804-7809	abuse	_
41-22	7810-7812	on	_
41-23	7813-7816	the	_
41-24	7817-7820	day	_
41-25	7821-7823	of	_
41-26	7824-7831	testing	_
41-27	7832-7833	(	_
41-28	7833-7842	screening	_
41-29	7843-7846	for	_
41-30	7847-7850	the	_
41-31	7851-7859	presence	_
41-32	7860-7862	of	_
41-33	7863-7875	amphetamines	_
41-34	7875-7876	,	_
41-35	7877-7892	benzodiazepines	_
41-36	7892-7893	,	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-37	7894-7906	cannabinoids	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-38	7906-7907	,	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-39	7908-7915	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-40	7916-7919	and	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-41	7920-7927	opiates	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-42	7927-7928	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-43	7928-7929	.	_

Text=The Mini-International Neuropsychiatric Interview (MINI) was administered to all participants by a trained psychiatrist to screen for the presence of Axis I psychiatric disorders that were part of the study exclusion criteria.
42-1	7930-7933	The	_
42-2	7934-7952	Mini-International	_
42-3	7953-7969	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
42-4	7970-7979	Interview	_
42-5	7980-7981	(	_
42-6	7981-7985	MINI	_
42-7	7985-7986	)	_
42-8	7987-7990	was	_
42-9	7991-8003	administered	_
42-10	8004-8006	to	_
42-11	8007-8010	all	_
42-12	8011-8023	participants	_
42-13	8024-8026	by	_
42-14	8027-8028	a	_
42-15	8029-8036	trained	_
42-16	8037-8049	psychiatrist	_
42-17	8050-8052	to	_
42-18	8053-8059	screen	_
42-19	8060-8063	for	_
42-20	8064-8067	the	_
42-21	8068-8076	presence	_
42-22	8077-8079	of	_
42-23	8080-8084	Axis	_
42-24	8085-8086	I	_
42-25	8087-8098	psychiatric	_
42-26	8099-8108	disorders	_
42-27	8109-8113	that	_
42-28	8114-8118	were	_
42-29	8119-8123	part	_
42-30	8124-8126	of	_
42-31	8127-8130	the	_
42-32	8131-8136	study	_
42-33	8137-8146	exclusion	_
42-34	8147-8155	criteria	_
42-35	8155-8156	.	_

Text=Exclusion criteria included 1) current use of regular prescription or non-prescription medication that could not be stopped; 2) current primary axis I diagnosis, past history of psychosis (unless drug-induced); 3) current or past history of enduring severe mental illness (e.g., schizophrenia, bipolar affective disorder); 4) other current or past psychiatric history that, in the opinion of a psychiatrist, contraindicated participation; 5) history or presence of a significant neurological diagnosis that may have influenced the outcome or analysis of the results; 6) claustrophobia or unable to lie still in the MRI scanner for up to 90   min and 7) presence of a cardiac pacemaker, other electronic device or other MRI contraindication, including pregnancy, as assessed by a standard pre-MRI questionnaire.
43-1	8157-8166	Exclusion	_
43-2	8167-8175	criteria	_
43-3	8176-8184	included	_
43-4	8185-8186	1	_
43-5	8186-8187	)	_
43-6	8188-8195	current	_
43-7	8196-8199	use	_
43-8	8200-8202	of	_
43-9	8203-8210	regular	_
43-10	8211-8223	prescription	_
43-11	8224-8226	or	_
43-12	8227-8243	non-prescription	_
43-13	8244-8254	medication	_
43-14	8255-8259	that	_
43-15	8260-8265	could	_
43-16	8266-8269	not	_
43-17	8270-8272	be	_
43-18	8273-8280	stopped	_
43-19	8280-8281	;	_
43-20	8282-8283	2	_
43-21	8283-8284	)	_
43-22	8285-8292	current	_
43-23	8293-8300	primary	_
43-24	8301-8305	axis	_
43-25	8306-8307	I	_
43-26	8308-8317	diagnosis	_
43-27	8317-8318	,	_
43-28	8319-8323	past	_
43-29	8324-8331	history	_
43-30	8332-8334	of	_
43-31	8335-8344	psychosis	_
43-32	8345-8346	(	_
43-33	8346-8352	unless	_
43-34	8353-8365	drug-induced	_
43-35	8365-8366	)	_
43-36	8366-8367	;	_
43-37	8368-8369	3	_
43-38	8369-8370	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-39	8371-8378	current	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-40	8379-8381	or	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-41	8382-8386	past	_
43-42	8387-8394	history	_
43-43	8395-8397	of	_
43-44	8398-8406	enduring	_
43-45	8407-8413	severe	_
43-46	8414-8420	mental	_
43-47	8421-8428	illness	_
43-48	8429-8430	(	_
43-49	8430-8433	e.g	_
43-50	8433-8434	.	_
43-51	8434-8435	,	_
43-52	8436-8449	schizophrenia	_
43-53	8449-8450	,	_
43-54	8451-8458	bipolar	_
43-55	8459-8468	affective	_
43-56	8469-8477	disorder	_
43-57	8477-8478	)	_
43-58	8478-8479	;	_
43-59	8480-8481	4	_
43-60	8481-8482	)	_
43-61	8483-8488	other	_
43-62	8489-8496	current	_
43-63	8497-8499	or	_
43-64	8500-8504	past	_
43-65	8505-8516	psychiatric	_
43-66	8517-8524	history	_
43-67	8525-8529	that	_
43-68	8529-8530	,	_
43-69	8531-8533	in	_
43-70	8534-8537	the	_
43-71	8538-8545	opinion	_
43-72	8546-8548	of	_
43-73	8549-8550	a	_
43-74	8551-8563	psychiatrist	_
43-75	8563-8564	,	_
43-76	8565-8580	contraindicated	_
43-77	8581-8594	participation	_
43-78	8594-8595	;	_
43-79	8596-8597	5	_
43-80	8597-8598	)	_
43-81	8599-8606	history	_
43-82	8607-8609	or	_
43-83	8610-8618	presence	_
43-84	8619-8621	of	_
43-85	8622-8623	a	_
43-86	8624-8635	significant	_
43-87	8636-8648	neurological	_
43-88	8649-8658	diagnosis	_
43-89	8659-8663	that	_
43-90	8664-8667	may	_
43-91	8668-8672	have	_
43-92	8673-8683	influenced	_
43-93	8684-8687	the	_
43-94	8688-8695	outcome	_
43-95	8696-8698	or	_
43-96	8699-8707	analysis	_
43-97	8708-8710	of	_
43-98	8711-8714	the	_
43-99	8715-8722	results	_
43-100	8722-8723	;	_
43-101	8724-8725	6	_
43-102	8725-8726	)	_
43-103	8727-8741	claustrophobia	_
43-104	8742-8744	or	_
43-105	8745-8751	unable	_
43-106	8752-8754	to	_
43-107	8755-8758	lie	_
43-108	8759-8764	still	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
43-109	8765-8767	in	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
43-110	8768-8771	the	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
43-111	8772-8775	MRI	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
43-112	8776-8783	scanner	_
43-113	8784-8787	for	_
43-114	8788-8790	up	_
43-115	8791-8793	to	_
43-116	8794-8796	90	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-117	8796-8797	 	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-118	8797-8800	min	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-119	8801-8804	and	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-120	8805-8806	7	_
43-121	8806-8807	)	_
43-122	8808-8816	presence	_
43-123	8817-8819	of	_
43-124	8820-8821	a	_
43-125	8822-8829	cardiac	_
43-126	8830-8839	pacemaker	_
43-127	8839-8840	,	_
43-128	8841-8846	other	_
43-129	8847-8857	electronic	_
43-130	8858-8864	device	_
43-131	8865-8867	or	_
43-132	8868-8873	other	_
43-133	8874-8877	MRI	_
43-134	8878-8894	contraindication	_
43-135	8894-8895	,	_
43-136	8896-8905	including	_
43-137	8906-8915	pregnancy	_
43-138	8915-8916	,	_
43-139	8917-8919	as	_
43-140	8920-8928	assessed	_
43-141	8929-8931	by	_
43-142	8932-8933	a	_
43-143	8934-8942	standard	_
43-144	8943-8950	pre-MRI	_
43-145	8951-8964	questionnaire	_
43-146	8964-8965	.	_

Text=Secondary or lifetime history of depression or anxiety was permitted in both the ADD and CON groups since these are very common psychiatric disorders.
44-1	8966-8975	Secondary	_
44-2	8976-8978	or	_
44-3	8979-8987	lifetime	_
44-4	8988-8995	history	_
44-5	8996-8998	of	_
44-6	8999-9009	depression	_
44-7	9010-9012	or	_
44-8	9013-9020	anxiety	_
44-9	9021-9024	was	_
44-10	9025-9034	permitted	_
44-11	9035-9037	in	_
44-12	9038-9042	both	_
44-13	9043-9046	the	_
44-14	9047-9050	ADD	_
44-15	9051-9054	and	_
44-16	9055-9058	CON	_
44-17	9059-9065	groups	_
44-18	9066-9071	since	_
44-19	9072-9077	these	_
44-20	9078-9081	are	_
44-21	9082-9086	very	_
44-22	9087-9093	common	_
44-23	9094-9105	psychiatric	_
44-24	9106-9115	disorders	_
44-25	9115-9116	.	_

Text=All participants provided written informed consent.
45-1	9117-9120	All	_
45-2	9121-9133	participants	_
45-3	9134-9142	provided	_
45-4	9143-9150	written	_
45-5	9151-9159	informed	_
45-6	9160-9167	consent	_
45-7	9167-9168	.	_

Text=The study was conducted in accordance with the Declaration of Helsinki.
46-1	9169-9172	The	_
46-2	9173-9178	study	_
46-3	9179-9182	was	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
46-4	9183-9192	conducted	_
46-5	9193-9195	in	_
46-6	9196-9206	accordance	_
46-7	9207-9211	with	_
46-8	9212-9215	the	_
46-9	9216-9227	Declaration	_
46-10	9228-9230	of	_
46-11	9231-9239	Helsinki	_
46-12	9239-9240	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging

Text=Ethical approval was obtained from West London and Gene Therapy Advisory Committee National Research Ethics Service Committee (11 / H0707 / 9) and relevant research governance and Participant Identification Centre (PIC) approvals obtained.
47-1	9241-9248	Ethical	_
47-2	9249-9257	approval	_
47-3	9258-9261	was	_
47-4	9262-9270	obtained	_
47-5	9271-9275	from	_
47-6	9276-9280	West	_
47-7	9281-9287	London	_
47-8	9288-9291	and	_
47-9	9292-9296	Gene	_
47-10	9297-9304	Therapy	_
47-11	9305-9313	Advisory	_
47-12	9314-9323	Committee	_
47-13	9324-9332	National	_
47-14	9333-9341	Research	_
47-15	9342-9348	Ethics	_
47-16	9349-9356	Service	_
47-17	9357-9366	Committee	_
47-18	9367-9368	(	_
47-19	9368-9370	11	_
47-20	9370-9371	/	_
47-21	9371-9376	H0707	_
47-22	9376-9377	/	_
47-23	9377-9378	9	_
47-24	9378-9379	)	_
47-25	9380-9383	and	_
47-26	9384-9392	relevant	_
47-27	9393-9401	research	_
47-28	9402-9412	governance	_
47-29	9413-9416	and	_
47-30	9417-9428	Participant	_
47-31	9429-9443	Identification	_
47-32	9444-9450	Centre	_
47-33	9451-9452	(	_
47-34	9452-9455	PIC	_
47-35	9455-9456	)	_
47-36	9457-9466	approvals	_
47-37	9467-9475	obtained	_
47-38	9475-9476	.	_

Text=Monetary incentive delay task (MID) We used a “ monetary incentive delay task ” (MID), which was based on that originally employed by Knutson, and which we have used to already publish data from the ICCAM platform.
48-1	9477-9485	Monetary	_
48-2	9486-9495	incentive	_
48-3	9496-9501	delay	_
48-4	9502-9506	task	_
48-5	9507-9508	(	_
48-6	9508-9511	MID	_
48-7	9511-9512	)	_
48-8	9513-9515	We	_
48-9	9516-9520	used	_
48-10	9521-9522	a	_
48-11	9523-9524	“	_
48-12	9524-9532	monetary	_
48-13	9533-9542	incentive	_
48-14	9543-9548	delay	_
48-15	9549-9553	task	_
48-16	9553-9554	”	_
48-17	9555-9556	(	_
48-18	9556-9559	MID	_
48-19	9559-9560	)	_
48-20	9560-9561	,	_
48-21	9562-9567	which	_
48-22	9568-9571	was	_
48-23	9572-9577	based	_
48-24	9578-9580	on	_
48-25	9581-9585	that	_
48-26	9586-9596	originally	_
48-27	9597-9605	employed	_
48-28	9606-9608	by	_
48-29	9609-9616	Knutson	_
48-30	9616-9617	,	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-31	9618-9621	and	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-32	9622-9627	which	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-33	9628-9630	we	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-34	9631-9635	have	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
48-35	9636-9640	used	_
48-36	9641-9643	to	_
48-37	9644-9651	already	_
48-38	9652-9659	publish	_
48-39	9660-9664	data	_
48-40	9665-9669	from	_
48-41	9670-9673	the	_
48-42	9674-9679	ICCAM	_
48-43	9680-9688	platform	_
48-44	9688-9689	.	_

Text=At the beginning of each trial, participants viewed one of three symbols (a cue) that indicated the potential to gain fifty pence (square containing an ascending arrow), lose fifty pence (square containing a descending arrow) or experience no financial outcome (square containing a horizontal line - here referred to as a neutral trial).
49-1	9690-9692	At	_
49-2	9693-9696	the	_
49-3	9697-9706	beginning	_
49-4	9707-9709	of	_
49-5	9710-9714	each	_
49-6	9715-9720	trial	_
49-7	9720-9721	,	_
49-8	9722-9734	participants	_
49-9	9735-9741	viewed	_
49-10	9742-9745	one	_
49-11	9746-9748	of	_
49-12	9749-9754	three	_
49-13	9755-9762	symbols	_
49-14	9763-9764	(	_
49-15	9764-9765	a	_
49-16	9766-9769	cue	_
49-17	9769-9770	)	_
49-18	9771-9775	that	_
49-19	9776-9785	indicated	_
49-20	9786-9789	the	_
49-21	9790-9799	potential	_
49-22	9800-9802	to	_
49-23	9803-9807	gain	_
49-24	9808-9813	fifty	_
49-25	9814-9819	pence	_
49-26	9820-9821	(	_
49-27	9821-9827	square	_
49-28	9828-9838	containing	_
49-29	9839-9841	an	_
49-30	9842-9851	ascending	_
49-31	9852-9857	arrow	_
49-32	9857-9858	)	_
49-33	9858-9859	,	_
49-34	9860-9864	lose	_
49-35	9865-9870	fifty	_
49-36	9871-9876	pence	_
49-37	9877-9878	(	_
49-38	9878-9884	square	_
49-39	9885-9895	containing	_
49-40	9896-9897	a	_
49-41	9898-9908	descending	_
49-42	9909-9914	arrow	_
49-43	9914-9915	)	_
49-44	9916-9918	or	_
49-45	9919-9929	experience	_
49-46	9930-9932	no	_
49-47	9933-9942	financial	_
49-48	9943-9950	outcome	_
49-49	9951-9952	(	_
49-50	9952-9958	square	_
49-51	9959-9969	containing	_
49-52	9970-9971	a	_
49-53	9972-9982	horizontal	_
49-54	9983-9987	line	_
49-55	9988-9989	-	_
49-56	9990-9994	here	_
49-57	9995-10003	referred	_
49-58	10004-10006	to	_
49-59	10007-10009	as	_
49-60	10010-10011	a	_
49-61	10012-10019	neutral	_
49-62	10020-10025	trial	_
49-63	10025-10026	)	_
49-64	10026-10027	.	_

Text=Each cue was presented for one second, with a variable duration (2 – 4   s) for the subsequent anticipation period.
50-1	10028-10032	Each	_
50-2	10033-10036	cue	_
50-3	10037-10040	was	_
50-4	10041-10050	presented	_
50-5	10051-10054	for	_
50-6	10055-10058	one	_
50-7	10059-10065	second	_
50-8	10065-10066	,	_
50-9	10067-10071	with	_
50-10	10072-10073	a	_
50-11	10074-10082	variable	_
50-12	10083-10091	duration	_
50-13	10092-10093	(	_
50-14	10093-10094	2	_
50-15	10094-10095	–	_
50-16	10095-10096	4	_
50-17	10096-10097	 	_
50-18	10097-10098	s	_
50-19	10098-10099	)	_
50-20	10100-10103	for	_
50-21	10104-10107	the	_
50-22	10108-10118	subsequent	_
50-23	10119-10131	anticipation	_
50-24	10132-10138	period	_
50-25	10138-10139	.	_

Text=Following the anticipation period, participants made a button press response upon the presentation of a visual target (star located within a circle).
51-1	10140-10149	Following	_
51-2	10150-10153	the	_
51-3	10154-10166	anticipation	_
51-4	10167-10173	period	_
51-5	10173-10174	,	_
51-6	10175-10187	participants	_
51-7	10188-10192	made	_
51-8	10193-10194	a	_
51-9	10195-10201	button	_
51-10	10202-10207	press	_
51-11	10208-10216	response	_
51-12	10217-10221	upon	_
51-13	10222-10225	the	_
51-14	10226-10238	presentation	_
51-15	10239-10241	of	_
51-16	10242-10243	a	_
51-17	10244-10250	visual	_
51-18	10251-10257	target	_
51-19	10258-10259	(	_
51-20	10259-10263	star	_
51-21	10264-10271	located	_
51-22	10272-10278	within	_
51-23	10279-10280	a	_
51-24	10281-10287	circle	_
51-25	10287-10288	)	_
51-26	10288-10289	.	_

Text=Following their response to the visual target, participants received feedback (1.5   s) as to whether they were successful (“ Hit ”) or unsuccessful (“ Miss ”) on that trial and saw a running total of their winnings up to that point in the task.
52-1	10290-10299	Following	_
52-2	10300-10305	their	_
52-3	10306-10314	response	_
52-4	10315-10317	to	_
52-5	10318-10321	the	_
52-6	10322-10328	visual	_
52-7	10329-10335	target	_
52-8	10335-10336	,	_
52-9	10337-10349	participants	_
52-10	10350-10358	received	_
52-11	10359-10367	feedback	_
52-12	10368-10369	(	_
52-13	10369-10372	1.5	_
52-14	10372-10373	 	_
52-15	10373-10374	s	_
52-16	10374-10375	)	_
52-17	10376-10378	as	_
52-18	10379-10381	to	_
52-19	10382-10389	whether	_
52-20	10390-10394	they	_
52-21	10395-10399	were	_
52-22	10400-10410	successful	_
52-23	10411-10412	(	_
52-24	10412-10413	“	_
52-25	10413-10416	Hit	_
52-26	10416-10417	”	_
52-27	10417-10418	)	_
52-28	10419-10421	or	_
52-29	10422-10434	unsuccessful	_
52-30	10435-10436	(	_
52-31	10436-10437	“	_
52-32	10437-10441	Miss	_
52-33	10441-10442	”	_
52-34	10442-10443	)	_
52-35	10444-10446	on	_
52-36	10447-10451	that	_
52-37	10452-10457	trial	_
52-38	10458-10461	and	_
52-39	10462-10465	saw	_
52-40	10466-10467	a	_
52-41	10468-10475	running	_
52-42	10476-10481	total	_
52-43	10482-10484	of	_
52-44	10485-10490	their	_
52-45	10491-10499	winnings	_
52-46	10500-10502	up	_
52-47	10503-10505	to	_
52-48	10506-10510	that	_
52-49	10511-10516	point	_
52-50	10517-10519	in	_
52-51	10520-10523	the	_
52-52	10524-10528	task	_
52-53	10528-10529	.	_

Text=Following feedback, there was an end fixation period (3 – 5   s) before the commencement of the next trial.
53-1	10530-10539	Following	_
53-2	10540-10548	feedback	_
53-3	10548-10549	,	_
53-4	10550-10555	there	_
53-5	10556-10559	was	_
53-6	10560-10562	an	_
53-7	10563-10566	end	_
53-8	10567-10575	fixation	_
53-9	10576-10582	period	_
53-10	10583-10584	(	_
53-11	10584-10585	3	_
53-12	10585-10586	–	_
53-13	10586-10587	5	_
53-14	10587-10588	 	_
53-15	10588-10589	s	_
53-16	10589-10590	)	_
53-17	10591-10597	before	_
53-18	10598-10601	the	_
53-19	10602-10614	commencement	_
53-20	10615-10617	of	_
53-21	10618-10621	the	_
53-22	10622-10626	next	_
53-23	10627-10632	trial	_
53-24	10632-10633	.	_

Text=Because the primary objective of ICCAM was to examine the neural correlates of reward anticipation, we chose to use a smaller number of loss trials in order to amplify the incentive salience of the gain trials during the task.
54-1	10634-10641	Because	_
54-2	10642-10645	the	_
54-3	10646-10653	primary	_
54-4	10654-10663	objective	_
54-5	10664-10666	of	_
54-6	10667-10672	ICCAM	_
54-7	10673-10676	was	_
54-8	10677-10679	to	_
54-9	10680-10687	examine	_
54-10	10688-10691	the	_
54-11	10692-10698	neural	_
54-12	10699-10709	correlates	_
54-13	10710-10712	of	_
54-14	10713-10719	reward	_
54-15	10720-10732	anticipation	_
54-16	10732-10733	,	_
54-17	10734-10736	we	_
54-18	10737-10742	chose	_
54-19	10743-10745	to	_
54-20	10746-10749	use	_
54-21	10750-10751	a	_
54-22	10752-10759	smaller	_
54-23	10760-10766	number	_
54-24	10767-10769	of	_
54-25	10770-10774	loss	_
54-26	10775-10781	trials	_
54-27	10782-10784	in	_
54-28	10785-10790	order	_
54-29	10791-10793	to	_
54-30	10794-10801	amplify	_
54-31	10802-10805	the	_
54-32	10806-10815	incentive	_
54-33	10816-10824	salience	_
54-34	10825-10827	of	_
54-35	10828-10831	the	_
54-36	10832-10836	gain	_
54-37	10837-10843	trials	_
54-38	10844-10850	during	_
54-39	10851-10854	the	_
54-40	10855-10859	task	_
54-41	10859-10860	.	_

Text=Consequently, there was a total of 18 gain, 6 lose and 18 neutral trials on each run of the task.
55-1	10861-10873	Consequently	_
55-2	10873-10874	,	_
55-3	10875-10880	there	_
55-4	10881-10884	was	_
55-5	10885-10886	a	_
55-6	10887-10892	total	_
55-7	10893-10895	of	_
55-8	10896-10898	18	_
55-9	10899-10903	gain	_
55-10	10903-10904	,	_
55-11	10905-10906	6	_
55-12	10907-10911	lose	_
55-13	10912-10915	and	_
55-14	10916-10918	18	_
55-15	10919-10926	neutral	_
55-16	10927-10933	trials	_
55-17	10934-10936	on	_
55-18	10937-10941	each	_
55-19	10942-10945	run	_
55-20	10946-10948	of	_
55-21	10949-10952	the	_
55-22	10953-10957	task	_
55-23	10957-10958	.	_

Text=The MID task was tailored to adapt to the visual target reaction time of each participant by using a staircase algorithm, such that the presentation of the visual target became shorter as performance improved during the experiment.
56-1	10959-10962	The	_
56-2	10963-10966	MID	_
56-3	10967-10971	task	_
56-4	10972-10975	was	_
56-5	10976-10984	tailored	_
56-6	10985-10987	to	_
56-7	10988-10993	adapt	_
56-8	10994-10996	to	_
56-9	10997-11000	the	_
56-10	11001-11007	visual	_
56-11	11008-11014	target	_
56-12	11015-11023	reaction	_
56-13	11024-11028	time	_
56-14	11029-11031	of	_
56-15	11032-11036	each	_
56-16	11037-11048	participant	_
56-17	11049-11051	by	_
56-18	11052-11057	using	_
56-19	11058-11059	a	_
56-20	11060-11069	staircase	_
56-21	11070-11079	algorithm	_
56-22	11079-11080	,	_
56-23	11081-11085	such	_
56-24	11086-11090	that	_
56-25	11091-11094	the	_
56-26	11095-11107	presentation	_
56-27	11108-11110	of	_
56-28	11111-11114	the	_
56-29	11115-11121	visual	_
56-30	11122-11128	target	_
56-31	11129-11135	became	_
56-32	11136-11143	shorter	_
56-33	11144-11146	as	_
56-34	11147-11158	performance	_
56-35	11159-11167	improved	_
56-36	11168-11174	during	_
56-37	11175-11178	the	_
56-38	11179-11189	experiment	_
56-39	11189-11190	.	_

Text=This enabled us to set a limit on the success rate of each participant (∼ 66%), which additionally served to incentivize participants to engage in the task.
57-1	11191-11195	This	_
57-2	11196-11203	enabled	_
57-3	11204-11206	us	_
57-4	11207-11209	to	_
57-5	11210-11213	set	_
57-6	11214-11215	a	_
57-7	11216-11221	limit	_
57-8	11222-11224	on	_
57-9	11225-11228	the	_
57-10	11229-11236	success	_
57-11	11237-11241	rate	_
57-12	11242-11244	of	_
57-13	11245-11249	each	_
57-14	11250-11261	participant	_
57-15	11262-11263	(	_
57-16	11263-11264	∼	_
57-17	11264-11267	66%	_
57-18	11267-11268	)	_
57-19	11268-11269	,	_
57-20	11270-11275	which	_
57-21	11276-11288	additionally	_
57-22	11289-11295	served	_
57-23	11296-11298	to	_
57-24	11299-11310	incentivize	_
57-25	11311-11323	participants	_
57-26	11324-11326	to	_
57-27	11327-11333	engage	_
57-28	11334-11336	in	_
57-29	11337-11340	the	_
57-30	11341-11345	task	_
57-31	11345-11346	.	_

Text=Participants were instructed to maximize their winnings and were told they would receive them at the end of the study.
58-1	11347-11359	Participants	_
58-2	11360-11364	were	_
58-3	11365-11375	instructed	_
58-4	11376-11378	to	_
58-5	11379-11387	maximize	_
58-6	11388-11393	their	_
58-7	11394-11402	winnings	_
58-8	11403-11406	and	_
58-9	11407-11411	were	_
58-10	11412-11416	told	_
58-11	11417-11421	they	_
58-12	11422-11427	would	_
58-13	11428-11435	receive	_
58-14	11436-11440	them	_
58-15	11441-11443	at	_
58-16	11444-11447	the	_
58-17	11448-11451	end	_
58-18	11452-11454	of	_
58-19	11455-11458	the	_
58-20	11459-11464	study	_
58-21	11464-11465	.	_

Text=Dependent measures were accuracy (percentage) and mean reaction time (milliseconds) to the visual target on each of the gain, lose and neutral trials, and the amount won (£) on the task.
59-1	11466-11475	Dependent	_
59-2	11476-11484	measures	_
59-3	11485-11489	were	_
59-4	11490-11498	accuracy	_
59-5	11499-11500	(	_
59-6	11500-11510	percentage	_
59-7	11510-11511	)	_
59-8	11512-11515	and	_
59-9	11516-11520	mean	_
59-10	11521-11529	reaction	_
59-11	11530-11534	time	_
59-12	11535-11536	(	_
59-13	11536-11548	milliseconds	_
59-14	11548-11549	)	_
59-15	11550-11552	to	_
59-16	11553-11556	the	_
59-17	11557-11563	visual	_
59-18	11564-11570	target	_
59-19	11571-11573	on	_
59-20	11574-11578	each	_
59-21	11579-11581	of	_
59-22	11582-11585	the	_
59-23	11586-11590	gain	_
59-24	11590-11591	,	_
59-25	11592-11596	lose	_
59-26	11597-11600	and	_
59-27	11601-11608	neutral	_
59-28	11609-11615	trials	_
59-29	11615-11616	,	_
59-30	11617-11620	and	_
59-31	11621-11624	the	_
59-32	11625-11631	amount	_
59-33	11632-11635	won	_
59-34	11636-11637	(	_
59-35	11637-11638	£	_
59-36	11638-11639	)	_
59-37	11640-11642	on	_
59-38	11643-11646	the	_
59-39	11647-11651	task	_
59-40	11651-11652	.	_

Text=Participants completed two runs of the task (432   s each) during scanning.
60-1	11653-11665	Participants	_
60-2	11666-11675	completed	_
60-3	11676-11679	two	_
60-4	11680-11684	runs	_
60-5	11685-11687	of	_
60-6	11688-11691	the	_
60-7	11692-11696	task	_
60-8	11697-11698	(	_
60-9	11698-11701	432	_
60-10	11701-11702	 	_
60-11	11702-11703	s	_
60-12	11704-11708	each	_
60-13	11708-11709	)	_
60-14	11710-11716	during	_
60-15	11717-11725	scanning	_
60-16	11725-11726	.	_

Text=The task was programmed using E-Prime version 2.0 (Psychology Software Tools, Pittsburgh, USA).
61-1	11727-11730	The	_
61-2	11731-11735	task	_
61-3	11736-11739	was	_
61-4	11740-11750	programmed	_
61-5	11751-11756	using	_
61-6	11757-11764	E-Prime	_
61-7	11765-11772	version	_
61-8	11773-11776	2.0	_
61-9	11777-11778	(	_
61-10	11778-11788	Psychology	_
61-11	11789-11797	Software	_
61-12	11798-11803	Tools	_
61-13	11803-11804	,	_
61-14	11805-11815	Pittsburgh	_
61-15	11815-11816	,	_
61-16	11817-11820	USA	_
61-17	11820-11821	)	_
61-18	11821-11822	.	_

Text=Statistics Group demographics were compared using simple independent samples t-test analyses.
62-1	11823-11833	Statistics	_
62-2	11834-11839	Group	_
62-3	11840-11852	demographics	_
62-4	11853-11857	were	_
62-5	11858-11866	compared	_
62-6	11867-11872	using	_
62-7	11873-11879	simple	_
62-8	11880-11891	independent	_
62-9	11892-11899	samples	_
62-10	11900-11906	t-test	_
62-11	11907-11915	analyses	_
62-12	11915-11916	.	_

Text=For analyses conducted on MID performance, two (Group: CON vs.
63-1	11917-11920	For	_
63-2	11921-11929	analyses	_
63-3	11930-11939	conducted	_
63-4	11940-11942	on	_
63-5	11943-11946	MID	_
63-6	11947-11958	performance	_
63-7	11958-11959	,	_
63-8	11960-11963	two	_
63-9	11964-11965	(	_
63-10	11965-11970	Group	_
63-11	11970-11971	:	_
63-12	11972-11975	CON	_
63-13	11976-11978	vs	_
63-14	11978-11979	.	_

Text=ADD) by two (Condition: Gain vs.
64-1	11980-11983	ADD	_
64-2	11983-11984	)	_
64-3	11985-11987	by	_
64-4	11988-11991	two	_
64-5	11992-11993	(	_
64-6	11993-12002	Condition	_
64-7	12002-12003	:	_
64-8	12004-12008	Gain	_
64-9	12009-12011	vs	_
64-10	12011-12012	.	_

Text=Neutral) analyses of variance were conducted.
65-1	12013-12020	Neutral	_
65-2	12020-12021	)	_
65-3	12022-12030	analyses	_
65-4	12031-12033	of	_
65-5	12034-12042	variance	_
65-6	12043-12047	were	_
65-7	12048-12057	conducted	_
65-8	12057-12058	.	_

Text=The CON and ADD groups were also compared on the lose accuracy and lose reaction time performance measures, as well as the amount of money won (£), using analyses of variance.
66-1	12059-12062	The	_
66-2	12063-12066	CON	_
66-3	12067-12070	and	_
66-4	12071-12074	ADD	_
66-5	12075-12081	groups	_
66-6	12082-12086	were	_
66-7	12087-12091	also	_
66-8	12092-12100	compared	_
66-9	12101-12103	on	_
66-10	12104-12107	the	_
66-11	12108-12112	lose	_
66-12	12113-12121	accuracy	_
66-13	12122-12125	and	_
66-14	12126-12130	lose	_
66-15	12131-12139	reaction	_
66-16	12140-12144	time	_
66-17	12145-12156	performance	_
66-18	12157-12165	measures	_
66-19	12165-12166	,	_
66-20	12167-12169	as	_
66-21	12170-12174	well	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
66-22	12175-12177	as	_
66-23	12178-12181	the	_
66-24	12182-12188	amount	_
66-25	12189-12191	of	_
66-26	12192-12197	money	_
66-27	12198-12201	won	_
66-28	12202-12203	(	_
66-29	12203-12204	£	_
66-30	12204-12205	)	_
66-31	12205-12206	,	_
66-32	12207-12212	using	_
66-33	12213-12221	analyses	_
66-34	12222-12224	of	_
66-35	12225-12233	variance	_
66-36	12233-12234	.	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse

Text=These analyses were conducted controlling for study site.
67-1	12235-12240	These	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
67-2	12241-12249	analyses	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-3	12250-12254	were	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-4	12255-12264	conducted	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-5	12265-12276	controlling	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-6	12277-12280	for	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
67-7	12281-12286	study	_
67-8	12287-12291	site	_
67-9	12291-12292	.	_

Text=For the graph measures (see below) we conducted two (Group: CON vs.
68-1	12293-12296	For	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-2	12297-12300	the	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-3	12301-12306	graph	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-4	12307-12315	measures	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-5	12316-12317	(	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-6	12317-12320	see	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
68-7	12321-12326	below	_
68-8	12326-12327	)	_
68-9	12328-12330	we	_
68-10	12331-12340	conducted	_
68-11	12341-12344	two	_
68-12	12345-12346	(	_
68-13	12346-12351	Group	_
68-14	12351-12352	:	_
68-15	12353-12356	CON	_
68-16	12357-12359	vs	_
68-17	12359-12360	.	_

Text=ADD) by five (1   ⩽   K   ⩽   5) analyses of variance, while also controlling for study site.
69-1	12361-12364	ADD	_
69-2	12364-12365	)	_
69-3	12366-12368	by	_
69-4	12369-12373	five	_
69-5	12374-12375	(	_
69-6	12375-12376	1	_
69-7	12376-12377	 	_
69-8	12377-12378	⩽	_
69-9	12378-12379	 	_
69-10	12379-12380	K	_
69-11	12380-12381	 	_
69-12	12381-12382	⩽	_
69-13	12382-12383	 	_
69-14	12383-12384	5	_
69-15	12384-12385	)	_
69-16	12386-12394	analyses	_
69-17	12395-12397	of	_
69-18	12398-12406	variance	_
69-19	12406-12407	,	_
69-20	12408-12413	while	_
69-21	12414-12418	also	_
69-22	12419-12430	controlling	_
69-23	12431-12434	for	_
69-24	12435-12440	study	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
69-25	12441-12445	site	_
69-26	12445-12446	.	_

Text=All these analyses were conducted using permutation testing (5000 iterations) in the R statistical software package (www.R-project.org).
70-1	12447-12450	All	_
70-2	12451-12456	these	_
70-3	12457-12465	analyses	_
70-4	12466-12470	were	_
70-5	12471-12480	conducted	_
70-6	12481-12486	using	_
70-7	12487-12498	permutation	_
70-8	12499-12506	testing	_
70-9	12507-12508	(	_
70-10	12508-12512	5000	_
70-11	12513-12523	iterations	_
70-12	12523-12524	)	_
70-13	12525-12527	in	_
70-14	12528-12531	the	_
70-15	12532-12533	R	_
70-16	12534-12545	statistical	_
70-17	12546-12554	software	_
70-18	12555-12562	package	_
70-19	12563-12564	(	_
70-20	12564-12581	www.R-project.org	_
70-21	12581-12582	)	_
70-22	12582-12583	.	_

Text=Functional MRI (fMRI) Data acquisition The ICCAM platform was designed to allow the rapid testing across sites of multiple compounds relevant to addiction treatment.
71-1	12584-12594	Functional	_
71-2	12595-12598	MRI	_
71-3	12599-12600	(	_
71-4	12600-12604	fMRI	_
71-5	12604-12605	)	_
71-6	12606-12610	Data	_
71-7	12611-12622	acquisition	_
71-8	12623-12626	The	_
71-9	12627-12632	ICCAM	_
71-10	12633-12641	platform	_
71-11	12642-12645	was	_
71-12	12646-12654	designed	_
71-13	12655-12657	to	_
71-14	12658-12663	allow	_
71-15	12664-12667	the	_
71-16	12668-12673	rapid	_
71-17	12674-12681	testing	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
71-18	12682-12688	across	_
71-19	12689-12694	sites	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
71-20	12695-12697	of	_
71-21	12698-12706	multiple	_
71-22	12707-12716	compounds	_
71-23	12717-12725	relevant	_
71-24	12726-12728	to	_
71-25	12729-12738	addiction	_
71-26	12739-12748	treatment	_
71-27	12748-12749	.	_

Text=Imaging at multiple sites in parallel on the ICCAM platform accelerated study completion, through the sharing of expertise, infrastructure and capacity.
72-1	12750-12757	Imaging	_
72-2	12758-12760	at	_
72-3	12761-12769	multiple	_
72-4	12770-12775	sites	_
72-5	12776-12778	in	_
72-6	12779-12787	parallel	_
72-7	12788-12790	on	_
72-8	12791-12794	the	_
72-9	12795-12800	ICCAM	_
72-10	12801-12809	platform	_
72-11	12810-12821	accelerated	_
72-12	12822-12827	study	_
72-13	12828-12838	completion	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
72-14	12838-12839	,	_
72-15	12840-12847	through	_
72-16	12848-12851	the	_
72-17	12852-12859	sharing	_
72-18	12860-12862	of	_
72-19	12863-12872	expertise	_
72-20	12872-12873	,	_
72-21	12874-12888	infrastructure	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
72-22	12889-12892	and	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
72-23	12893-12901	capacity	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
72-24	12901-12902	.	_
72-25	12902-12903	 	_

Text=For a more comprehensive description of data acquisition across the three sites on ICCAM, please see McGonigle et al.
73-1	12903-12906	For	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-2	12907-12908	a	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-3	12909-12913	more	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-4	12914-12927	comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-5	12928-12939	description	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
73-6	12940-12942	of	_
73-7	12943-12947	data	_
73-8	12948-12959	acquisition	_
73-9	12960-12966	across	_
73-10	12967-12970	the	_
73-11	12971-12976	three	_
73-12	12977-12982	sites	_
73-13	12983-12985	on	_
73-14	12986-12991	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-15	12991-12992	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-16	12993-12999	please	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-17	13000-13003	see	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-18	13004-13013	McGonigle	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
73-19	13014-13016	et	_
73-20	13017-13019	al	_
73-21	13019-13020	.	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging

Text=Briefly, all centres operated MRI machines with a main magnetic field of 3   T (T).
74-1	13021-13028	Briefly	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
74-2	13028-13029	,	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
74-3	13030-13033	all	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
74-4	13034-13041	centres	_
74-5	13042-13050	operated	_
74-6	13051-13054	MRI	_
74-7	13055-13063	machines	_
74-8	13064-13068	with	_
74-9	13069-13070	a	_
74-10	13071-13075	main	_
74-11	13076-13084	magnetic	_
74-12	13085-13090	field	_
74-13	13091-13093	of	_
74-14	13094-13095	3	_
74-15	13095-13096	 	_
74-16	13096-13097	T	_
74-17	13098-13099	(	_
74-18	13099-13100	T	_
74-19	13100-13101	)	_
74-20	13101-13102	.	_

Text=Centres in London and Cambridge operated nominally identical 3   T Siemens Tim Trio systems running the syngo MR B17 software with a Siemens 32 channel receive-only phased-array head coil.
75-1	13103-13110	Centres	_
75-2	13111-13113	in	_
75-3	13114-13120	London	_
75-4	13121-13124	and	_
75-5	13125-13134	Cambridge	_
75-6	13135-13143	operated	_
75-7	13144-13153	nominally	_
75-8	13154-13163	identical	_
75-9	13164-13165	3	_
75-10	13165-13166	 	_
75-11	13166-13167	T	_
75-12	13168-13175	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
75-13	13176-13179	Tim	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
75-14	13180-13184	Trio	_
75-15	13185-13192	systems	_
75-16	13193-13200	running	_
75-17	13201-13204	the	_
75-18	13205-13210	syngo	_
75-19	13211-13213	MR	_
75-20	13214-13217	B17	_
75-21	13218-13226	software	_
75-22	13227-13231	with	_
75-23	13232-13233	a	_
75-24	13234-13241	Siemens	_
75-25	13242-13244	32	_
75-26	13245-13252	channel	_
75-27	13253-13265	receive-only	_
75-28	13266-13278	phased-array	_
75-29	13279-13283	head	_
75-30	13284-13288	coil	_
75-31	13288-13289	.	_

Text=The Manchester centre operated a 3   T Philips Achieva running version 2.6.3.5 software and an 8 element SENSE head coil.
76-1	13290-13293	The	_
76-2	13294-13304	Manchester	_
76-3	13305-13311	centre	_
76-4	13312-13320	operated	_
76-5	13321-13322	a	_
76-6	13323-13324	3	_
76-7	13324-13325	 	_
76-8	13325-13326	T	_
76-9	13327-13334	Philips	_
76-10	13335-13342	Achieva	_
76-11	13343-13350	running	_
76-12	13351-13358	version	_
76-13	13359-13366	2.6.3.5	_
76-14	13367-13375	software	_
76-15	13376-13379	and	_
76-16	13380-13382	an	_
76-17	13383-13384	8	_
76-18	13385-13392	element	_
76-19	13393-13398	SENSE	_
76-20	13399-13403	head	_
76-21	13404-13408	coil	_
76-22	13408-13409	.	_

Text=For anatomical images, 160 high-resolution T1 - weighted anatomic MPRAGE axial images (FOV 256   mm, thickness 1.0   mm, voxel size 1.0   ×   1.0   ×   1.0) were acquired (total duration 303   s).
77-1	13410-13413	For	_
77-2	13414-13424	anatomical	_
77-3	13425-13431	images	_
77-4	13431-13432	,	_
77-5	13433-13436	160	_
77-6	13437-13452	high-resolution	_
77-7	13453-13455	T1	_
77-8	13455-13456	-	_
77-9	13456-13464	weighted	_
77-10	13465-13473	anatomic	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
77-11	13474-13480	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
77-12	13481-13486	axial	_
77-13	13487-13493	images	_
77-14	13494-13495	(	_
77-15	13495-13498	FOV	_
77-16	13499-13502	256	_
77-17	13502-13503	 	_
77-18	13503-13505	mm	_
77-19	13505-13506	,	_
77-20	13507-13516	thickness	_
77-21	13517-13520	1.0	_
77-22	13520-13521	 	_
77-23	13521-13523	mm	_
77-24	13523-13524	,	_
77-25	13525-13530	voxel	_
77-26	13531-13535	size	_
77-27	13536-13539	1.0	_
77-28	13539-13540	 	_
77-29	13540-13541	×	_
77-30	13541-13542	 	_
77-31	13542-13545	1.0	_
77-32	13545-13546	 	_
77-33	13546-13547	×	_
77-34	13547-13548	 	_
77-35	13548-13551	1.0	_
77-36	13551-13552	)	_
77-37	13553-13557	were	_
77-38	13558-13566	acquired	_
77-39	13567-13568	(	_
77-40	13568-13573	total	_
77-41	13574-13582	duration	_
77-42	13583-13586	303	_
77-43	13586-13587	 	_
77-44	13587-13588	s	_
77-45	13588-13589	)	_
77-46	13589-13590	.	_

Text=Functional data were acquired using a T2 * weighted echo-planar imaging sequence collecting 36 non-contiguous (0% gap) 3.0   mm axial slices covering the entire brain (TE   =   31   ms, TR   =   2000   ms, FOV 225   mm, 64   ×   64   mm matrix size in Fourier space).
78-1	13591-13601	Functional	_
78-2	13602-13606	data	_
78-3	13607-13611	were	_
78-4	13612-13620	acquired	_
78-5	13621-13626	using	_
78-6	13627-13628	a	_
78-7	13629-13631	T2	_
78-8	13631-13632	*	_
78-9	13633-13641	weighted	_
78-10	13642-13653	echo-planar	_
78-11	13654-13661	imaging	_
78-12	13662-13670	sequence	_
78-13	13671-13681	collecting	_
78-14	13682-13684	36	_
78-15	13685-13699	non-contiguous	_
78-16	13700-13701	(	_
78-17	13701-13703	0%	_
78-18	13704-13707	gap	_
78-19	13707-13708	)	_
78-20	13709-13712	3.0	_
78-21	13712-13713	 	_
78-22	13713-13715	mm	http://maven.renci.org/NeuroBridge/neurobridge#Thing
78-23	13716-13721	axial	_
78-24	13722-13728	slices	_
78-25	13729-13737	covering	_
78-26	13738-13741	the	_
78-27	13742-13748	entire	_
78-28	13749-13754	brain	_
78-29	13755-13756	(	_
78-30	13756-13758	TE	_
78-31	13758-13759	 	_
78-32	13759-13760	=	_
78-33	13760-13761	 	_
78-34	13761-13763	31	_
78-35	13763-13764	 	_
78-36	13764-13766	ms	_
78-37	13766-13767	,	_
78-38	13768-13770	TR	_
78-39	13770-13771	 	_
78-40	13771-13772	=	_
78-41	13772-13773	 	_
78-42	13773-13777	2000	_
78-43	13777-13778	 	_
78-44	13778-13780	ms	_
78-45	13780-13781	,	_
78-46	13782-13785	FOV	_
78-47	13786-13789	225	_
78-48	13789-13790	 	_
78-49	13790-13792	mm	_
78-50	13792-13793	,	_
78-51	13794-13796	64	_
78-52	13796-13797	 	_
78-53	13797-13798	×	_
78-54	13798-13799	 	_
78-55	13799-13801	64	_
78-56	13801-13802	 	_
78-57	13802-13804	mm	_
78-58	13805-13811	matrix	_
78-59	13812-13816	size	_
78-60	13817-13819	in	_
78-61	13820-13827	Fourier	_
78-62	13828-13833	space	_
78-63	13833-13834	)	_
78-64	13834-13835	.	_

Text=Each run of the MID task produced a total of 216 volumes of functional MRI data. fMRI Data analyses Data pre-processing and statistical analysis were conducted using FEAT (fMRI Expert Analysis Tool) from the FMRIB Software Library (www.fmrib.ox.ac.uk / fsl).
79-1	13836-13840	Each	_
79-2	13841-13844	run	_
79-3	13845-13847	of	_
79-4	13848-13851	the	_
79-5	13852-13855	MID	_
79-6	13856-13860	task	_
79-7	13861-13869	produced	_
79-8	13870-13871	a	_
79-9	13872-13877	total	_
79-10	13878-13880	of	_
79-11	13881-13884	216	_
79-12	13885-13892	volumes	_
79-13	13893-13895	of	_
79-14	13896-13906	functional	_
79-15	13907-13910	MRI	_
79-16	13911-13915	data	_
79-17	13915-13916	.	_
79-18	13917-13921	fMRI	_
79-19	13922-13926	Data	_
79-20	13927-13935	analyses	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-21	13936-13940	Data	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-22	13941-13955	pre-processing	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-23	13956-13959	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-24	13960-13971	statistical	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-25	13972-13980	analysis	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-26	13981-13985	were	_
79-27	13986-13995	conducted	_
79-28	13996-14001	using	_
79-29	14002-14006	FEAT	_
79-30	14007-14008	(	_
79-31	14008-14012	fMRI	_
79-32	14013-14019	Expert	_
79-33	14020-14028	Analysis	_
79-34	14029-14033	Tool	_
79-35	14033-14034	)	_
79-36	14035-14039	from	_
79-37	14040-14043	the	_
79-38	14044-14049	FMRIB	_
79-39	14050-14058	Software	_
79-40	14059-14066	Library	_
79-41	14067-14068	(	_
79-42	14068-14086	www.fmrib.ox.ac.uk	_
79-43	14086-14087	/	_
79-44	14087-14090	fsl	_
79-45	14090-14091	)	_
79-46	14091-14092	.	_

Text=Pre-statistical processing was as follows: motion correction utilizing FMRIB ’ s Linear Image Registration Tool (MCFLIRT; non-brain matter removal using Brain Extraction Tool (BET); spatial smoothing with a 5 - mm full-width half maximum Gaussian kernel; mean-based intensity normalization; nonlinear high-pass temporal filtering (Gaussian-weighted least squares straight line fit, with sigma   =   25.0   s).
80-1	14093-14108	Pre-statistical	_
80-2	14109-14119	processing	_
80-3	14120-14123	was	_
80-4	14124-14126	as	_
80-5	14127-14134	follows	_
80-6	14134-14135	:	_
80-7	14136-14142	motion	_
80-8	14143-14153	correction	_
80-9	14154-14163	utilizing	_
80-10	14164-14169	FMRIB	_
80-11	14169-14170	’	_
80-12	14170-14171	s	_
80-13	14172-14178	Linear	_
80-14	14179-14184	Image	_
80-15	14185-14197	Registration	_
80-16	14198-14202	Tool	_
80-17	14203-14204	(	_
80-18	14204-14211	MCFLIRT	_
80-19	14211-14212	;	_
80-20	14213-14222	non-brain	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
80-21	14223-14229	matter	_
80-22	14230-14237	removal	_
80-23	14238-14243	using	_
80-24	14244-14249	Brain	_
80-25	14250-14260	Extraction	_
80-26	14261-14265	Tool	_
80-27	14266-14267	(	_
80-28	14267-14270	BET	_
80-29	14270-14271	)	_
80-30	14271-14272	;	_
80-31	14273-14280	spatial	_
80-32	14281-14290	smoothing	_
80-33	14291-14295	with	_
80-34	14296-14297	a	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
80-35	14298-14299	5	_
80-36	14299-14300	-	_
80-37	14300-14302	mm	_
80-38	14303-14313	full-width	_
80-39	14314-14318	half	_
80-40	14319-14326	maximum	_
80-41	14327-14335	Gaussian	_
80-42	14336-14342	kernel	_
80-43	14342-14343	;	_
80-44	14344-14354	mean-based	_
80-45	14355-14364	intensity	_
80-46	14365-14378	normalization	_
80-47	14378-14379	;	_
80-48	14380-14389	nonlinear	_
80-49	14390-14399	high-pass	_
80-50	14400-14408	temporal	_
80-51	14409-14418	filtering	_
80-52	14419-14420	(	_
80-53	14420-14437	Gaussian-weighted	_
80-54	14438-14443	least	_
80-55	14444-14451	squares	_
80-56	14452-14460	straight	_
80-57	14461-14465	line	_
80-58	14466-14469	fit	_
80-59	14469-14470	,	_
80-60	14471-14475	with	_
80-61	14476-14481	sigma	_
80-62	14481-14482	 	_
80-63	14482-14483	=	_
80-64	14483-14484	 	_
80-65	14484-14488	25.0	_
80-66	14488-14489	 	_
80-67	14489-14490	s	_
80-68	14490-14491	)	_
80-69	14491-14492	.	_

Text=The six rigid body movement parameters were also included as regressors in the model in FSL FEAT.
81-1	14493-14496	The	_
81-2	14497-14500	six	_
81-3	14501-14506	rigid	_
81-4	14507-14511	body	_
81-5	14512-14520	movement	_
81-6	14521-14531	parameters	_
81-7	14532-14536	were	_
81-8	14537-14541	also	_
81-9	14542-14550	included	_
81-10	14551-14553	as	_
81-11	14554-14564	regressors	_
81-12	14565-14567	in	_
81-13	14568-14571	the	_
81-14	14572-14577	model	_
81-15	14578-14580	in	_
81-16	14581-14584	FSL	_
81-17	14585-14589	FEAT	_
81-18	14589-14590	.	_

Text=For each participant, first level whole-brain mixed-effects analyses were performed by modelling the MID anticipation periods (i.e. gain, neutral) as explanatory variables within the context of the general linear model on a voxel-by-voxel basis (variable boxcar functions for the cue   +   variable anticipation period regressors were convolved with the haemodynamic response function).
82-1	14591-14594	For	_
82-2	14595-14599	each	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-3	14600-14611	participant	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-4	14611-14612	,	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-5	14613-14618	first	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-6	14619-14624	level	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-7	14625-14636	whole-brain	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
82-8	14637-14650	mixed-effects	_
82-9	14651-14659	analyses	_
82-10	14660-14664	were	_
82-11	14665-14674	performed	_
82-12	14675-14677	by	_
82-13	14678-14687	modelling	_
82-14	14688-14691	the	_
82-15	14692-14695	MID	_
82-16	14696-14708	anticipation	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
82-17	14709-14716	periods	_
82-18	14717-14718	(	_
82-19	14718-14721	i.e	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
82-20	14721-14722	.	_
82-21	14723-14727	gain	_
82-22	14727-14728	,	_
82-23	14729-14736	neutral	_
82-24	14736-14737	)	_
82-25	14738-14740	as	_
82-26	14741-14752	explanatory	_
82-27	14753-14762	variables	_
82-28	14763-14769	within	_
82-29	14770-14773	the	_
82-30	14774-14781	context	_
82-31	14782-14784	of	_
82-32	14785-14788	the	_
82-33	14789-14796	general	_
82-34	14797-14803	linear	_
82-35	14804-14809	model	_
82-36	14810-14812	on	_
82-37	14813-14814	a	_
82-38	14815-14829	voxel-by-voxel	_
82-39	14830-14835	basis	_
82-40	14836-14837	(	_
82-41	14837-14845	variable	_
82-42	14846-14852	boxcar	_
82-43	14853-14862	functions	_
82-44	14863-14866	for	_
82-45	14867-14870	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
82-46	14871-14874	cue	_
82-47	14874-14875	 	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
82-48	14875-14876	+	_
82-49	14876-14877	 	_
82-50	14877-14885	variable	_
82-51	14886-14898	anticipation	_
82-52	14899-14905	period	_
82-53	14906-14916	regressors	_
82-54	14917-14921	were	_
82-55	14922-14931	convolved	_
82-56	14932-14936	with	_
82-57	14937-14940	the	_
82-58	14941-14953	haemodynamic	_
82-59	14954-14962	response	_
82-60	14963-14971	function	_
82-61	14971-14972	)	_
82-62	14972-14973	.	_

Text=The gain and neutral outcome periods (“ Hit ” and “ Miss ”) were regressed out of the functional time series as conditions of no interest for the analyses reported here.
83-1	14974-14977	The	_
83-2	14978-14982	gain	_
83-3	14983-14986	and	_
83-4	14987-14994	neutral	_
83-5	14995-15002	outcome	_
83-6	15003-15010	periods	_
83-7	15011-15012	(	_
83-8	15012-15013	“	_
83-9	15013-15016	Hit	_
83-10	15016-15017	”	_
83-11	15018-15021	and	_
83-12	15022-15023	“	_
83-13	15023-15027	Miss	_
83-14	15027-15028	”	_
83-15	15028-15029	)	_
83-16	15030-15034	were	_
83-17	15035-15044	regressed	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-18	15045-15048	out	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-19	15049-15051	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-20	15052-15055	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-21	15056-15066	functional	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-22	15067-15071	time	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-23	15072-15078	series	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-24	15079-15081	as	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-25	15082-15092	conditions	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-26	15093-15095	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-27	15096-15098	no	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
83-28	15099-15107	interest	_
83-29	15108-15111	for	_
83-30	15112-15115	the	_
83-31	15116-15124	analyses	_
83-32	15125-15133	reported	_
83-33	15134-15138	here	_
83-34	15138-15139	.	_

Text=During these first level analyses, the gain anticipation  >   neutral anticipation contrast was formulated.
84-1	15140-15146	During	_
84-2	15147-15152	these	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
84-3	15153-15158	first	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
84-4	15159-15164	level	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
84-5	15165-15173	analyses	_
84-6	15173-15174	,	_
84-7	15175-15178	the	_
84-8	15179-15183	gain	_
84-9	15184-15196	anticipation	_
84-10	15196-15197	 	_
84-11	15197-15198	>	_
84-12	15198-15199	 	_
84-13	15199-15206	neutral	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
84-14	15207-15219	anticipation	_
84-15	15220-15228	contrast	_
84-16	15229-15232	was	_
84-17	15233-15243	formulated	_
84-18	15243-15244	.	_

Text=Owing to the small number of loss trials in the current task, the lose cue   +   anticipation and outcome periods (“ Hit ” and “ Miss ”) were additionally regressed out of the functional time series as conditions of no interest.
85-1	15245-15250	Owing	_
85-2	15251-15253	to	_
85-3	15254-15257	the	_
85-4	15258-15263	small	_
85-5	15264-15270	number	_
85-6	15271-15273	of	_
85-7	15274-15278	loss	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
85-8	15279-15285	trials	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
85-9	15286-15288	in	_
85-10	15289-15292	the	_
85-11	15293-15300	current	_
85-12	15301-15305	task	_
85-13	15305-15306	,	_
85-14	15307-15310	the	_
85-15	15311-15315	lose	_
85-16	15316-15319	cue	_
85-17	15319-15320	 	_
85-18	15320-15321	+	_
85-19	15321-15322	 	_
85-20	15322-15334	anticipation	_
85-21	15335-15338	and	_
85-22	15339-15346	outcome	_
85-23	15347-15354	periods	_
85-24	15355-15356	(	_
85-25	15356-15357	“	_
85-26	15357-15360	Hit	_
85-27	15360-15361	”	_
85-28	15362-15365	and	_
85-29	15366-15367	“	_
85-30	15367-15371	Miss	_
85-31	15371-15372	”	_
85-32	15372-15373	)	_
85-33	15374-15378	were	_
85-34	15379-15391	additionally	_
85-35	15392-15401	regressed	_
85-36	15402-15405	out	_
85-37	15406-15408	of	_
85-38	15409-15412	the	_
85-39	15413-15423	functional	_
85-40	15424-15428	time	_
85-41	15429-15435	series	_
85-42	15436-15438	as	_
85-43	15439-15449	conditions	_
85-44	15450-15452	of	_
85-45	15453-15455	no	_
85-46	15456-15464	interest	_
85-47	15464-15465	.	_

Text=Therefore, the fewer number of lose trials on the MID task meant we were unable to examine voxel-wise group differences in loss anticipation.
86-1	15466-15475	Therefore	_
86-2	15475-15476	,	_
86-3	15477-15480	the	_
86-4	15481-15486	fewer	_
86-5	15487-15493	number	_
86-6	15494-15496	of	_
86-7	15497-15501	lose	_
86-8	15502-15508	trials	_
86-9	15509-15511	on	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
86-10	15512-15515	the	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
86-11	15516-15519	MID	_
86-12	15520-15524	task	_
86-13	15525-15530	meant	_
86-14	15531-15533	we	_
86-15	15534-15538	were	_
86-16	15539-15545	unable	_
86-17	15546-15548	to	_
86-18	15549-15556	examine	_
86-19	15557-15567	voxel-wise	_
86-20	15568-15573	group	_
86-21	15574-15585	differences	_
86-22	15586-15588	in	_
86-23	15589-15593	loss	_
86-24	15594-15606	anticipation	_
86-25	15606-15607	.	_

Text=The end fixation period of the task served as the implicit baseline.
87-1	15608-15611	The	_
87-2	15612-15615	end	_
87-3	15616-15624	fixation	_
87-4	15625-15631	period	_
87-5	15632-15634	of	_
87-6	15635-15638	the	_
87-7	15639-15643	task	_
87-8	15644-15650	served	_
87-9	15651-15653	as	_
87-10	15654-15657	the	_
87-11	15658-15666	implicit	_
87-12	15667-15675	baseline	_
87-13	15675-15676	.	_

Text=Registration was conducted through a two-step procedure, whereby EPI images were first registered to the high-resolution T1 structural image, then into standard (Montreal Neurological Institute, MNI avg152 template) space, with 12 - parameter affine transformations.
88-1	15677-15689	Registration	_
88-2	15690-15693	was	_
88-3	15694-15703	conducted	_
88-4	15704-15711	through	_
88-5	15712-15713	a	_
88-6	15714-15722	two-step	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
88-7	15723-15732	procedure	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
88-8	15732-15733	,	_
88-9	15734-15741	whereby	_
88-10	15742-15745	EPI	_
88-11	15746-15752	images	_
88-12	15753-15757	were	_
88-13	15758-15763	first	_
88-14	15764-15774	registered	_
88-15	15775-15777	to	_
88-16	15778-15781	the	_
88-17	15782-15797	high-resolution	_
88-18	15798-15800	T1	_
88-19	15801-15811	structural	_
88-20	15812-15817	image	_
88-21	15817-15818	,	_
88-22	15819-15823	then	_
88-23	15824-15828	into	_
88-24	15829-15837	standard	_
88-25	15838-15839	(	_
88-26	15839-15847	Montreal	_
88-27	15848-15860	Neurological	_
88-28	15861-15870	Institute	_
88-29	15870-15871	,	_
88-30	15872-15875	MNI	_
88-31	15876-15882	avg152	_
88-32	15883-15891	template	_
88-33	15891-15892	)	_
88-34	15893-15898	space	_
88-35	15898-15899	,	_
88-36	15900-15904	with	_
88-37	15905-15907	12	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
88-38	15907-15908	-	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
88-39	15908-15917	parameter	_
88-40	15918-15924	affine	_
88-41	15925-15940	transformations	_
88-42	15940-15941	.	_

Text=Higher-level (within group one-sample t-tests and between-group independent samples t-tests) were conducted on the gain anticipation  >   neutral anticipation contrast using the randomise programme in FSL.
89-1	15942-15954	Higher-level	_
89-2	15955-15956	(	_
89-3	15956-15962	within	_
89-4	15963-15968	group	_
89-5	15969-15979	one-sample	_
89-6	15980-15987	t-tests	_
89-7	15988-15991	and	_
89-8	15992-16005	between-group	_
89-9	16006-16017	independent	_
89-10	16018-16025	samples	_
89-11	16026-16033	t-tests	_
89-12	16033-16034	)	_
89-13	16035-16039	were	_
89-14	16040-16049	conducted	_
89-15	16050-16052	on	_
89-16	16053-16056	the	_
89-17	16057-16061	gain	_
89-18	16062-16074	anticipation	_
89-19	16074-16075	 	_
89-20	16075-16076	>	_
89-21	16076-16077	 	_
89-22	16077-16084	neutral	_
89-23	16085-16097	anticipation	_
89-24	16098-16106	contrast	_
89-25	16107-16112	using	_
89-26	16113-16116	the	_
89-27	16117-16126	randomise	_
89-28	16127-16136	programme	_
89-29	16137-16139	in	_
89-30	16140-16143	FSL	_
89-31	16143-16144	.	_

Text=Randomise employs a permutation approach through resampling.
90-1	16145-16154	Randomise	_
90-2	16155-16162	employs	_
90-3	16163-16164	a	_
90-4	16165-16176	permutation	_
90-5	16177-16185	approach	_
90-6	16186-16193	through	_
90-7	16194-16204	resampling	_
90-8	16204-16205	.	_

Text=Significance (PFWE   <  0.05) for the gain anticipation  >   neutral anticipation contrast on both the one-sample and independent samples t-tests was conducted taking a threshold-free cluster enhancement (TFCE) approach and using 5000 permutations.
91-1	16206-16218	Significance	_
91-2	16219-16220	(	_
91-3	16220-16224	PFWE	_
91-4	16224-16225	 	_
91-5	16225-16226	<	_
91-6	16226-16227	 	_
91-7	16227-16231	0.05	_
91-8	16231-16232	)	_
91-9	16233-16236	for	_
91-10	16237-16240	the	_
91-11	16241-16245	gain	_
91-12	16246-16258	anticipation	_
91-13	16258-16259	 	_
91-14	16259-16260	>	_
91-15	16260-16261	 	_
91-16	16261-16268	neutral	_
91-17	16269-16281	anticipation	_
91-18	16282-16290	contrast	_
91-19	16291-16293	on	_
91-20	16294-16298	both	_
91-21	16299-16302	the	_
91-22	16303-16313	one-sample	_
91-23	16314-16317	and	_
91-24	16318-16329	independent	_
91-25	16330-16337	samples	_
91-26	16338-16345	t-tests	_
91-27	16346-16349	was	_
91-28	16350-16359	conducted	_
91-29	16360-16366	taking	_
91-30	16367-16368	a	_
91-31	16369-16383	threshold-free	_
91-32	16384-16391	cluster	_
91-33	16392-16403	enhancement	_
91-34	16404-16405	(	_
91-35	16405-16409	TFCE	_
91-36	16409-16410	)	_
91-37	16411-16419	approach	_
91-38	16420-16423	and	_
91-39	16424-16429	using	_
91-40	16430-16434	5000	_
91-41	16435-16447	permutations	_
91-42	16447-16448	.	_

Text=TFCE aims to maintain the sensitivity of cluster-based thresholding, while avoiding the arbitrary nature of threshold choice.
92-1	16449-16453	TFCE	_
92-2	16454-16458	aims	_
92-3	16459-16461	to	_
92-4	16462-16470	maintain	_
92-5	16471-16474	the	_
92-6	16475-16486	sensitivity	_
92-7	16487-16489	of	_
92-8	16490-16503	cluster-based	_
92-9	16504-16516	thresholding	_
92-10	16516-16517	,	_
92-11	16518-16523	while	_
92-12	16524-16532	avoiding	_
92-13	16533-16536	the	_
92-14	16537-16546	arbitrary	_
92-15	16547-16553	nature	_
92-16	16554-16556	of	_
92-17	16557-16566	threshold	_
92-18	16567-16573	choice	_
92-19	16573-16574	.	_

Text=Given the differences in scanners across the three sites, these analyses were conducted while also controlling for study site.
93-1	16575-16580	Given	_
93-2	16581-16584	the	_
93-3	16585-16596	differences	_
93-4	16597-16599	in	_
93-5	16600-16608	scanners	_
93-6	16609-16615	across	_
93-7	16616-16619	the	_
93-8	16620-16625	three	_
93-9	16626-16631	sites	_
93-10	16631-16632	,	_
93-11	16633-16638	these	_
93-12	16639-16647	analyses	_
93-13	16648-16652	were	_
93-14	16653-16662	conducted	_
93-15	16663-16668	while	_
93-16	16669-16673	also	_
93-17	16674-16685	controlling	_
93-18	16686-16689	for	_
93-19	16690-16695	study	_
93-20	16696-16700	site	_
93-21	16700-16701	.	_

Text=Trial-Wise beta value image analyses Data pre-processing was also initially conducted using FEAT (fMRI Expert Analysis Tool) from the FMRIB Software Library (www.fmrib.ox.ac.uk / fsl) as described above.
94-1	16702-16712	Trial-Wise	_
94-2	16713-16717	beta	_
94-3	16718-16723	value	_
94-4	16724-16729	image	_
94-5	16730-16738	analyses	_
94-6	16739-16743	Data	_
94-7	16744-16758	pre-processing	_
94-8	16759-16762	was	_
94-9	16763-16767	also	_
94-10	16768-16777	initially	_
94-11	16778-16787	conducted	_
94-12	16788-16793	using	_
94-13	16794-16798	FEAT	_
94-14	16799-16800	(	_
94-15	16800-16804	fMRI	_
94-16	16805-16811	Expert	_
94-17	16812-16820	Analysis	_
94-18	16821-16825	Tool	_
94-19	16825-16826	)	_
94-20	16827-16831	from	_
94-21	16832-16835	the	_
94-22	16836-16841	FMRIB	_
94-23	16842-16850	Software	_
94-24	16851-16858	Library	_
94-25	16859-16860	(	_
94-26	16860-16878	www.fmrib.ox.ac.uk	_
94-27	16878-16879	/	_
94-28	16879-16882	fsl	_
94-29	16882-16883	)	_
94-30	16884-16886	as	_
94-31	16887-16896	described	_
94-32	16897-16902	above	_
94-33	16902-16903	.	_

Text=For each participant, each individual gain and neutral anticipation epoch (cue   +   variable anticipation period) was separately modelled within the context of the general linear model.
95-1	16904-16907	For	_
95-2	16908-16912	each	_
95-3	16913-16924	participant	_
95-4	16924-16925	,	_
95-5	16926-16930	each	_
95-6	16931-16941	individual	_
95-7	16942-16946	gain	_
95-8	16947-16950	and	_
95-9	16951-16958	neutral	_
95-10	16959-16971	anticipation	_
95-11	16972-16977	epoch	_
95-12	16978-16979	(	_
95-13	16979-16982	cue	_
95-14	16982-16983	 	_
95-15	16983-16984	+	_
95-16	16984-16985	 	_
95-17	16985-16993	variable	_
95-18	16994-17006	anticipation	_
95-19	17007-17013	period	_
95-20	17013-17014	)	_
95-21	17015-17018	was	_
95-22	17019-17029	separately	_
95-23	17030-17038	modelled	_
95-24	17039-17045	within	_
95-25	17046-17049	the	_
95-26	17050-17057	context	_
95-27	17058-17060	of	_
95-28	17061-17064	the	_
95-29	17065-17072	general	_
95-30	17073-17079	linear	_
95-31	17080-17085	model	_
95-32	17085-17086	.	_

Text=This approach yielded a total of 18 unique beta value images for each of the gain and neutral anticipation conditions on each run of the MID task.
96-1	17087-17091	This	_
96-2	17092-17100	approach	_
96-3	17101-17108	yielded	_
96-4	17109-17110	a	_
96-5	17111-17116	total	_
96-6	17117-17119	of	_
96-7	17120-17122	18	_
96-8	17123-17129	unique	_
96-9	17130-17134	beta	_
96-10	17135-17140	value	_
96-11	17141-17147	images	_
96-12	17148-17151	for	_
96-13	17152-17156	each	_
96-14	17157-17159	of	_
96-15	17160-17163	the	_
96-16	17164-17168	gain	_
96-17	17169-17172	and	_
96-18	17173-17180	neutral	_
96-19	17181-17193	anticipation	_
96-20	17194-17204	conditions	_
96-21	17205-17207	on	_
96-22	17208-17212	each	_
96-23	17213-17216	run	_
96-24	17217-17219	of	_
96-25	17220-17223	the	_
96-26	17224-17227	MID	_
96-27	17228-17232	task	_
96-28	17232-17233	.	_

Text=This meant that each voxel-wise beta value image reflected the magnitude of the hemodynamic response evoked by each of the gain and neutral anticipation epochs.
97-1	17234-17238	This	_
97-2	17239-17244	meant	_
97-3	17245-17249	that	_
97-4	17250-17254	each	_
97-5	17255-17265	voxel-wise	_
97-6	17266-17270	beta	_
97-7	17271-17276	value	_
97-8	17277-17282	image	_
97-9	17283-17292	reflected	_
97-10	17293-17296	the	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
97-11	17297-17306	magnitude	_
97-12	17307-17309	of	_
97-13	17310-17313	the	_
97-14	17314-17325	hemodynamic	_
97-15	17326-17334	response	_
97-16	17335-17341	evoked	_
97-17	17342-17344	by	_
97-18	17345-17349	each	_
97-19	17350-17352	of	_
97-20	17353-17356	the	_
97-21	17357-17361	gain	_
97-22	17362-17365	and	_
97-23	17366-17373	neutral	_
97-24	17374-17386	anticipation	_
97-25	17387-17393	epochs	_
97-26	17393-17394	.	_

Text=Each beta value image for each MID run was then subsequently registered into standard (MNI avg152 template) space before being concatenated to generate a beta value “ trial-wise ” (e.g., gain anticipation) time series.
98-1	17395-17399	Each	_
98-2	17400-17404	beta	_
98-3	17405-17410	value	_
98-4	17411-17416	image	_
98-5	17417-17420	for	_
98-6	17421-17425	each	_
98-7	17426-17429	MID	_
98-8	17430-17433	run	_
98-9	17434-17437	was	_
98-10	17438-17442	then	_
98-11	17443-17455	subsequently	_
98-12	17456-17466	registered	_
98-13	17467-17471	into	_
98-14	17472-17480	standard	_
98-15	17481-17482	(	_
98-16	17482-17485	MNI	_
98-17	17486-17492	avg152	_
98-18	17493-17501	template	_
98-19	17501-17502	)	_
98-20	17503-17508	space	_
98-21	17509-17515	before	_
98-22	17516-17521	being	_
98-23	17522-17534	concatenated	_
98-24	17535-17537	to	_
98-25	17538-17546	generate	_
98-26	17547-17548	a	_
98-27	17549-17553	beta	_
98-28	17554-17559	value	_
98-29	17560-17561	“	_
98-30	17561-17571	trial-wise	_
98-31	17571-17572	”	_
98-32	17573-17574	(	_
98-33	17574-17577	e.g	_
98-34	17577-17578	.	_
98-35	17578-17579	,	_
98-36	17580-17584	gain	_
98-37	17585-17597	anticipation	_
98-38	17597-17598	)	_
98-39	17599-17603	time	_
98-40	17604-17610	series	_
98-41	17610-17611	.	_

Text=Each beta value trial-wise time series for each MID run was further concatenated across runs to generate a single beta value trial-wise time series for the gain and neutral MID anticipation conditions.
99-1	17612-17616	Each	_
99-2	17617-17621	beta	_
99-3	17622-17627	value	_
99-4	17628-17638	trial-wise	_
99-5	17639-17643	time	_
99-6	17644-17650	series	_
99-7	17651-17654	for	_
99-8	17655-17659	each	_
99-9	17660-17663	MID	_
99-10	17664-17667	run	_
99-11	17668-17671	was	_
99-12	17672-17679	further	_
99-13	17680-17692	concatenated	_
99-14	17693-17699	across	_
99-15	17700-17704	runs	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-16	17705-17707	to	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-17	17708-17716	generate	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-18	17717-17718	a	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-19	17719-17725	single	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
99-20	17726-17730	beta	_
99-21	17731-17736	value	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
99-22	17737-17747	trial-wise	_
99-23	17748-17752	time	_
99-24	17753-17759	series	_
99-25	17760-17763	for	_
99-26	17764-17767	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-27	17768-17772	gain	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-28	17773-17776	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-29	17777-17784	neutral	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-30	17785-17788	MID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-31	17789-17801	anticipation	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-32	17802-17812	conditions	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
99-33	17812-17813	.	_

Text=This procedure yielded a thirty-six beta value trial-wise time series image for each participant for the gain and neutral anticipation conditions.
100-1	17814-17818	This	_
100-2	17819-17828	procedure	http://maven.renci.org/NeuroBridge/neurobridge#Thing
100-3	17829-17836	yielded	_
100-4	17837-17838	a	_
100-5	17839-17849	thirty-six	_
100-6	17850-17854	beta	_
100-7	17855-17860	value	_
100-8	17861-17871	trial-wise	_
100-9	17872-17876	time	_
100-10	17877-17883	series	_
100-11	17884-17889	image	_
100-12	17890-17893	for	_
100-13	17894-17898	each	_
100-14	17899-17910	participant	_
100-15	17911-17914	for	_
100-16	17915-17918	the	_
100-17	17919-17923	gain	_
100-18	17924-17927	and	_
100-19	17928-17935	neutral	_
100-20	17936-17948	anticipation	_
100-21	17949-17959	conditions	_
100-22	17959-17960	.	_

Text=The neutral trial-wise time series was then simply subtracted from the gain trial-wise time series to yield a gain anticipation  >   neutral anticipation contrast time series (see Supplementary Fig. 1).
101-1	17961-17964	The	_
101-2	17965-17972	neutral	_
101-3	17973-17983	trial-wise	_
101-4	17984-17988	time	_
101-5	17989-17995	series	_
101-6	17996-17999	was	_
101-7	18000-18004	then	_
101-8	18005-18011	simply	_
101-9	18012-18022	subtracted	_
101-10	18023-18027	from	_
101-11	18028-18031	the	_
101-12	18032-18036	gain	_
101-13	18037-18047	trial-wise	_
101-14	18048-18052	time	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-15	18053-18059	series	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-16	18060-18062	to	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-17	18063-18068	yield	_
101-18	18069-18070	a	_
101-19	18071-18075	gain	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
101-20	18076-18088	anticipation	_
101-21	18088-18089	 	_
101-22	18089-18090	>	_
101-23	18090-18091	 	_
101-24	18091-18098	neutral	_
101-25	18099-18111	anticipation	_
101-26	18112-18120	contrast	_
101-27	18121-18125	time	_
101-28	18126-18132	series	_
101-29	18133-18134	(	_
101-30	18134-18137	see	_
101-31	18138-18151	Supplementary	_
101-32	18152-18155	Fig	_
101-33	18155-18156	.	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-34	18157-18158	1	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-35	18158-18159	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
101-36	18159-18160	.	_

Text=This beta value trial-wise time series method has been previously used to examine connectivity during cognitive tasks, including the MID task.
102-1	18161-18165	This	_
102-2	18166-18170	beta	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
102-3	18171-18176	value	_
102-4	18177-18187	trial-wise	_
102-5	18188-18192	time	_
102-6	18193-18199	series	_
102-7	18200-18206	method	_
102-8	18207-18210	has	_
102-9	18211-18215	been	http://maven.renci.org/NeuroBridge/neurobridge#Thing
102-10	18216-18226	previously	_
102-11	18227-18231	used	_
102-12	18232-18234	to	_
102-13	18235-18242	examine	_
102-14	18243-18255	connectivity	_
102-15	18256-18262	during	_
102-16	18263-18272	cognitive	_
102-17	18273-18278	tasks	_
102-18	18278-18279	,	_
102-19	18280-18289	including	_
102-20	18290-18293	the	_
102-21	18294-18297	MID	_
102-22	18298-18302	task	_
102-23	18302-18303	.	_

Text=The small, variable (performance-dependent) number of events for the outcome periods (“ hits ” and “ misses ”), and the small number of loss trials in the task, meant that we could not generate trial-wise beta value images for these events.
103-1	18304-18307	The	_
103-2	18308-18313	small	_
103-3	18313-18314	,	_
103-4	18315-18323	variable	_
103-5	18324-18325	(	_
103-6	18325-18346	performance-dependent	_
103-7	18346-18347	)	_
103-8	18348-18354	number	_
103-9	18355-18357	of	_
103-10	18358-18364	events	_
103-11	18365-18368	for	_
103-12	18369-18372	the	_
103-13	18373-18380	outcome	_
103-14	18381-18388	periods	_
103-15	18389-18390	(	_
103-16	18390-18391	“	_
103-17	18391-18395	hits	_
103-18	18395-18396	”	_
103-19	18397-18400	and	_
103-20	18401-18402	“	_
103-21	18402-18408	misses	_
103-22	18408-18409	”	_
103-23	18409-18410	)	_
103-24	18410-18411	,	_
103-25	18412-18415	and	_
103-26	18416-18419	the	_
103-27	18420-18425	small	_
103-28	18426-18432	number	_
103-29	18433-18435	of	_
103-30	18436-18440	loss	_
103-31	18441-18447	trials	_
103-32	18448-18450	in	_
103-33	18451-18454	the	_
103-34	18455-18459	task	_
103-35	18459-18460	,	_
103-36	18461-18466	meant	_
103-37	18467-18471	that	_
103-38	18472-18474	we	_
103-39	18475-18480	could	_
103-40	18481-18484	not	_
103-41	18485-18493	generate	_
103-42	18494-18504	trial-wise	_
103-43	18505-18509	beta	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
103-44	18510-18515	value	_
103-45	18516-18522	images	_
103-46	18523-18526	for	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
103-47	18527-18532	these	_
103-48	18533-18539	events	_
103-49	18539-18540	.	_

Text=Therefore, gain and neutral outcome (well as lose anticipation and outcome) events were regressed out of the functional time series as conditions of no interest during the first level analyses.
104-1	18541-18550	Therefore	_
104-2	18550-18551	,	_
104-3	18552-18556	gain	_
104-4	18557-18560	and	_
104-5	18561-18568	neutral	_
104-6	18569-18576	outcome	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
104-7	18577-18578	(	_
104-8	18578-18582	well	_
104-9	18583-18585	as	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
104-10	18586-18590	lose	_
104-11	18591-18603	anticipation	_
104-12	18604-18607	and	_
104-13	18608-18615	outcome	_
104-14	18615-18616	)	_
104-15	18617-18623	events	_
104-16	18624-18628	were	_
104-17	18629-18638	regressed	_
104-18	18639-18642	out	_
104-19	18643-18645	of	_
104-20	18646-18649	the	_
104-21	18650-18660	functional	_
104-22	18661-18665	time	_
104-23	18666-18672	series	_
104-24	18673-18675	as	_
104-25	18676-18686	conditions	_
104-26	18687-18689	of	_
104-27	18690-18692	no	_
104-28	18693-18701	interest	_
104-29	18702-18708	during	_
104-30	18709-18712	the	_
104-31	18713-18718	first	http://maven.renci.org/NeuroBridge/neurobridge#Age
104-32	18719-18724	level	_
104-33	18725-18733	analyses	_
104-34	18733-18734	.	_

Text=This meant that the same end fixation period of the task also served as the implicit baseline for these analyses.
105-1	18735-18739	This	_
105-2	18740-18745	meant	_
105-3	18746-18750	that	_
105-4	18751-18754	the	_
105-5	18755-18759	same	_
105-6	18760-18763	end	_
105-7	18764-18772	fixation	_
105-8	18773-18779	period	_
105-9	18780-18782	of	_
105-10	18783-18786	the	_
105-11	18787-18791	task	_
105-12	18792-18796	also	_
105-13	18797-18803	served	_
105-14	18804-18806	as	_
105-15	18807-18810	the	_
105-16	18811-18819	implicit	_
105-17	18820-18828	baseline	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
105-18	18829-18832	for	_
105-19	18833-18838	these	_
105-20	18839-18847	analyses	_
105-21	18847-18848	.	_

Text=Time series Extraction and correlation matrices Using the Harvard-Oxford atlas (96 cortical and 14 subcortical nodes / regions) as our connectome of interest, we used the fslmeants programme to extract the mean beta value time series from each of 110 anatomical regions of interest (ROI) for the gain anticipation  >   neutral contrast beta image for each participant.
106-1	18849-18853	Time	_
106-2	18854-18860	series	_
106-3	18861-18871	Extraction	_
106-4	18872-18875	and	_
106-5	18876-18887	correlation	_
106-6	18888-18896	matrices	_
106-7	18897-18902	Using	_
106-8	18903-18906	the	_
106-9	18907-18921	Harvard-Oxford	_
106-10	18922-18927	atlas	http://maven.renci.org/NeuroBridge/neurobridge#Thing
106-11	18928-18929	(	_
106-12	18929-18931	96	_
106-13	18932-18940	cortical	_
106-14	18941-18944	and	_
106-15	18945-18947	14	_
106-16	18948-18959	subcortical	_
106-17	18960-18965	nodes	_
106-18	18965-18966	/	_
106-19	18966-18973	regions	_
106-20	18973-18974	)	_
106-21	18975-18977	as	_
106-22	18978-18981	our	_
106-23	18982-18992	connectome	_
106-24	18993-18995	of	_
106-25	18996-19004	interest	_
106-26	19004-19005	,	_
106-27	19006-19008	we	_
106-28	19009-19013	used	_
106-29	19014-19017	the	_
106-30	19018-19027	fslmeants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
106-31	19028-19037	programme	_
106-32	19038-19040	to	_
106-33	19041-19048	extract	_
106-34	19049-19052	the	_
106-35	19053-19057	mean	_
106-36	19058-19062	beta	_
106-37	19063-19068	value	_
106-38	19069-19073	time	_
106-39	19074-19080	series	_
106-40	19081-19085	from	_
106-41	19086-19090	each	_
106-42	19091-19093	of	_
106-43	19094-19097	110	_
106-44	19098-19108	anatomical	_
106-45	19109-19116	regions	_
106-46	19117-19119	of	_
106-47	19120-19128	interest	_
106-48	19129-19130	(	_
106-49	19130-19133	ROI	_
106-50	19133-19134	)	_
106-51	19135-19138	for	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
106-52	19139-19142	the	_
106-53	19143-19147	gain	_
106-54	19148-19160	anticipation	_
106-55	19160-19161	 	_
106-56	19161-19162	>	_
106-57	19162-19163	 	_
106-58	19163-19170	neutral	_
106-59	19171-19179	contrast	_
106-60	19180-19184	beta	_
106-61	19185-19190	image	_
106-62	19191-19194	for	_
106-63	19195-19199	each	_
106-64	19200-19211	participant	_
106-65	19211-19212	.	_

Text=Using these mean ROI time series outputs, we then conducted Pearson correlation coefficient analyses to construct whole brain ROI‐to‐ROI pairwise matrices (see Supplementary Fig. 1).
107-1	19213-19218	Using	_
107-2	19219-19224	these	_
107-3	19225-19229	mean	_
107-4	19230-19233	ROI	_
107-5	19234-19238	time	_
107-6	19239-19245	series	_
107-7	19246-19253	outputs	_
107-8	19253-19254	,	_
107-9	19255-19257	we	_
107-10	19258-19262	then	_
107-11	19263-19272	conducted	_
107-12	19273-19280	Pearson	_
107-13	19281-19292	correlation	_
107-14	19293-19304	coefficient	_
107-15	19305-19313	analyses	_
107-16	19314-19316	to	_
107-17	19317-19326	construct	_
107-18	19327-19332	whole	_
107-19	19333-19338	brain	_
107-20	19339-19349	ROI‐to‐ROI	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
107-21	19350-19358	pairwise	_
107-22	19359-19367	matrices	_
107-23	19368-19369	(	_
107-24	19369-19372	see	_
107-25	19373-19386	Supplementary	_
107-26	19387-19390	Fig	_
107-27	19390-19391	.	_
107-28	19392-19393	1	_
107-29	19393-19394	)	_
107-30	19394-19395	.	_

Text=Each matrix was made up of 5995 (= N * (N   −   1) / 2, with N   =   110 nodes) pairwise connections (edges).
108-1	19396-19400	Each	_
108-2	19401-19407	matrix	_
108-3	19408-19411	was	_
108-4	19412-19416	made	_
108-5	19417-19419	up	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
108-6	19420-19422	of	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
108-7	19423-19427	5995	_
108-8	19428-19429	(	_
108-9	19429-19430	=	_
108-10	19430-19431	N	_
108-11	19431-19432	*	_
108-12	19432-19433	(	_
108-13	19433-19434	N	_
108-14	19434-19435	 	_
108-15	19435-19436	−	_
108-16	19436-19437	 	_
108-17	19437-19438	1	_
108-18	19438-19439	)	_
108-19	19439-19440	/	_
108-20	19440-19441	2	_
108-21	19441-19442	,	_
108-22	19443-19447	with	_
108-23	19448-19449	N	_
108-24	19449-19450	 	_
108-25	19450-19451	=	_
108-26	19451-19452	 	_
108-27	19452-19455	110	_
108-28	19456-19461	nodes	_
108-29	19461-19462	)	_
108-30	19463-19471	pairwise	_
108-31	19472-19483	connections	_
108-32	19484-19485	(	_
108-33	19485-19490	edges	_
108-34	19490-19491	)	_
108-35	19491-19492	.	_

Text=These matrices were generated in MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States) and used to compare network connectivity between the CON and ADD groups (see below).
109-1	19493-19498	These	_
109-2	19499-19507	matrices	_
109-3	19508-19512	were	_
109-4	19513-19522	generated	_
109-5	19523-19525	in	_
109-6	19526-19532	MATLAB	_
109-7	19533-19534	(	_
109-8	19534-19537	The	_
109-9	19538-19547	MathWorks	_
109-10	19547-19548	,	_
109-11	19549-19552	Inc	_
109-12	19552-19553	.	_
109-13	19553-19554	,	_
109-14	19555-19561	Natick	_
109-15	19561-19562	,	_
109-16	19563-19576	Massachusetts	_
109-17	19576-19577	,	_
109-18	19578-19584	United	_
109-19	19585-19591	States	_
109-20	19591-19592	)	_
109-21	19593-19596	and	_
109-22	19597-19601	used	_
109-23	19602-19604	to	_
109-24	19605-19612	compare	_
109-25	19613-19620	network	_
109-26	19621-19633	connectivity	_
109-27	19634-19641	between	_
109-28	19642-19645	the	_
109-29	19646-19649	CON	_
109-30	19650-19653	and	_
109-31	19654-19657	ADD	_
109-32	19658-19664	groups	_
109-33	19665-19666	(	_
109-34	19666-19669	see	_
109-35	19670-19675	below	_
109-36	19675-19676	)	_
109-37	19676-19677	.	_

Text=Graph measures Global (characteristic path length and clustering coefficient) graph measures were estimated from each correlation matrix using the GraphVar (www.rfmri.org / GraphVar) toolbox for functional brain connectivity in MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States).
110-1	19678-19683	Graph	_
110-2	19684-19692	measures	_
110-3	19693-19699	Global	_
110-4	19700-19701	(	_
110-5	19701-19715	characteristic	_
110-6	19716-19720	path	_
110-7	19721-19727	length	_
110-8	19728-19731	and	_
110-9	19732-19742	clustering	_
110-10	19743-19754	coefficient	_
110-11	19754-19755	)	_
110-12	19756-19761	graph	_
110-13	19762-19770	measures	_
110-14	19771-19775	were	_
110-15	19776-19785	estimated	_
110-16	19786-19790	from	_
110-17	19791-19795	each	_
110-18	19796-19807	correlation	_
110-19	19808-19814	matrix	_
110-20	19815-19820	using	_
110-21	19821-19824	the	_
110-22	19825-19833	GraphVar	_
110-23	19834-19835	(	_
110-24	19835-19848	www.rfmri.org	_
110-25	19848-19849	/	_
110-26	19849-19857	GraphVar	_
110-27	19857-19858	)	_
110-28	19859-19866	toolbox	_
110-29	19867-19870	for	_
110-30	19871-19881	functional	_
110-31	19882-19887	brain	_
110-32	19888-19900	connectivity	_
110-33	19901-19903	in	_
110-34	19904-19910	MATLAB	_
110-35	19911-19912	(	_
110-36	19912-19915	The	_
110-37	19916-19925	MathWorks	_
110-38	19925-19926	,	_
110-39	19927-19930	Inc	_
110-40	19930-19931	.	_
110-41	19931-19932	,	_
110-42	19933-19939	Natick	_
110-43	19939-19940	,	_
110-44	19941-19954	Massachusetts	_
110-45	19954-19955	,	_
110-46	19956-19962	United	_
110-47	19963-19969	States	_
110-48	19969-19970	)	_
110-49	19970-19971	.	_

Text=More detailed descriptions of brain network graph measures can be found elsewhere, but we will briefly describe these metrics here.
111-1	19972-19976	More	_
111-2	19977-19985	detailed	_
111-3	19986-19998	descriptions	_
111-4	19999-20001	of	_
111-5	20002-20007	brain	_
111-6	20008-20015	network	_
111-7	20016-20021	graph	_
111-8	20022-20030	measures	_
111-9	20031-20034	can	_
111-10	20035-20037	be	_
111-11	20038-20043	found	_
111-12	20044-20053	elsewhere	_
111-13	20053-20054	,	_
111-14	20055-20058	but	_
111-15	20059-20061	we	_
111-16	20062-20066	will	_
111-17	20067-20074	briefly	_
111-18	20075-20083	describe	_
111-19	20084-20089	these	_
111-20	20090-20097	metrics	_
111-21	20098-20102	here	_
111-22	20102-20103	.	_

Text=Characteristic path length is the minimum number of edges that must be traversed to go from one node (brain region) to another in a network.
112-1	20104-20118	Characteristic	_
112-2	20119-20123	path	_
112-3	20124-20130	length	_
112-4	20131-20133	is	_
112-5	20134-20137	the	_
112-6	20138-20145	minimum	_
112-7	20146-20152	number	_
112-8	20153-20155	of	_
112-9	20156-20161	edges	_
112-10	20162-20166	that	_
112-11	20167-20171	must	_
112-12	20172-20174	be	_
112-13	20175-20184	traversed	_
112-14	20185-20187	to	_
112-15	20188-20190	go	_
112-16	20191-20195	from	_
112-17	20196-20199	one	_
112-18	20200-20204	node	_
112-19	20205-20206	(	_
112-20	20206-20211	brain	_
112-21	20212-20218	region	_
112-22	20218-20219	)	_
112-23	20220-20222	to	_
112-24	20223-20230	another	_
112-25	20231-20233	in	_
112-26	20234-20235	a	_
112-27	20236-20243	network	_
112-28	20243-20244	.	_

Text=For a pair of nodes that are nearest neighbours, the path length is 1.
113-1	20245-20248	For	_
113-2	20249-20250	a	_
113-3	20251-20255	pair	_
113-4	20256-20258	of	_
113-5	20259-20264	nodes	_
113-6	20265-20269	that	_
113-7	20270-20273	are	_
113-8	20274-20281	nearest	_
113-9	20282-20292	neighbours	_
113-10	20292-20293	,	_
113-11	20294-20297	the	_
113-12	20298-20302	path	_
113-13	20303-20309	length	_
113-14	20310-20312	is	_
113-15	20313-20314	1	_
113-16	20314-20315	.	_

Text=The clustering coefficient, by contrast, quantifies the density of connections between the nearest neighbour of a node, and describes how segregated the network is.
114-1	20316-20319	The	_
114-2	20320-20330	clustering	_
114-3	20331-20342	coefficient	_
114-4	20342-20343	,	_
114-5	20344-20346	by	_
114-6	20347-20355	contrast	_
114-7	20355-20356	,	_
114-8	20357-20367	quantifies	_
114-9	20368-20371	the	_
114-10	20372-20379	density	_
114-11	20380-20382	of	_
114-12	20383-20394	connections	_
114-13	20395-20402	between	_
114-14	20403-20406	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
114-15	20407-20414	nearest	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
114-16	20415-20424	neighbour	_
114-17	20425-20427	of	_
114-18	20428-20429	a	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
114-19	20430-20434	node	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
114-20	20434-20435	,	_
114-21	20436-20439	and	_
114-22	20440-20449	describes	_
114-23	20450-20453	how	_
114-24	20454-20464	segregated	_
114-25	20465-20468	the	_
114-26	20469-20476	network	_
114-27	20477-20479	is	_
114-28	20479-20480	.	_

Text=The path and clustering measures are first estimated at each node of the connectome before an average (global value) is computed for the entire connectome for each participant ’ s correlation matrix.
115-1	20481-20484	The	_
115-2	20485-20489	path	_
115-3	20490-20493	and	_
115-4	20494-20504	clustering	_
115-5	20505-20513	measures	_
115-6	20514-20517	are	_
115-7	20518-20523	first	_
115-8	20524-20533	estimated	_
115-9	20534-20536	at	_
115-10	20537-20541	each	_
115-11	20542-20546	node	_
115-12	20547-20549	of	_
115-13	20550-20553	the	_
115-14	20554-20564	connectome	_
115-15	20565-20571	before	_
115-16	20572-20574	an	_
115-17	20575-20582	average	_
115-18	20583-20584	(	_
115-19	20584-20590	global	_
115-20	20591-20596	value	_
115-21	20596-20597	)	_
115-22	20598-20600	is	_
115-23	20601-20609	computed	_
115-24	20610-20613	for	_
115-25	20614-20617	the	_
115-26	20618-20624	entire	_
115-27	20625-20635	connectome	_
115-28	20636-20639	for	_
115-29	20640-20644	each	_
115-30	20645-20656	participant	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
115-31	20656-20657	’	_
115-32	20657-20658	s	_
115-33	20659-20670	correlation	_
115-34	20671-20677	matrix	_
115-35	20677-20678	.	_

Text=Graph measures for each participant were then estimated by thresholding each matrix at a selection of proportional cost (K) thresholds – i.e. thresholds that retain only a percentage of the strongest connections (edges) in the network.
116-1	20679-20684	Graph	_
116-2	20685-20693	measures	http://maven.renci.org/NeuroBridge/neurobridge#2Level
116-3	20694-20697	for	http://maven.renci.org/NeuroBridge/neurobridge#2Level
116-4	20698-20702	each	http://maven.renci.org/NeuroBridge/neurobridge#2Level
116-5	20703-20714	participant	_
116-6	20715-20719	were	_
116-7	20720-20724	then	_
116-8	20725-20734	estimated	_
116-9	20735-20737	by	_
116-10	20738-20750	thresholding	_
116-11	20751-20755	each	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
116-12	20756-20762	matrix	_
116-13	20763-20765	at	_
116-14	20766-20767	a	_
116-15	20768-20777	selection	_
116-16	20778-20780	of	_
116-17	20781-20793	proportional	_
116-18	20794-20798	cost	_
116-19	20799-20800	(	_
116-20	20800-20801	K	_
116-21	20801-20802	)	_
116-22	20803-20813	thresholds	_
116-23	20814-20815	–	_
116-24	20816-20819	i.e	_
116-25	20819-20820	.	_
116-26	20821-20831	thresholds	_
116-27	20832-20836	that	_
116-28	20837-20843	retain	_
116-29	20844-20848	only	_
116-30	20849-20850	a	_
116-31	20851-20861	percentage	_
116-32	20862-20864	of	_
116-33	20865-20868	the	_
116-34	20869-20878	strongest	_
116-35	20879-20890	connections	_
116-36	20891-20892	(	http://maven.renci.org/NeuroBridge/neurobridge#Asperger'sDisorder
116-37	20892-20897	edges	_
116-38	20897-20898	)	_
116-39	20899-20901	in	_
116-40	20902-20905	the	_
116-41	20906-20913	network	_
116-42	20913-20914	.	_

Text=Biological networks are represented by sparse connections, however, and thresholding is a necessary step to extract the appropriate topological properties of networks.
117-1	20915-20925	Biological	_
117-2	20926-20934	networks	_
117-3	20935-20938	are	_
117-4	20939-20950	represented	_
117-5	20951-20953	by	_
117-6	20954-20960	sparse	_
117-7	20961-20972	connections	_
117-8	20972-20973	,	_
117-9	20974-20981	however	_
117-10	20981-20982	,	_
117-11	20983-20986	and	_
117-12	20987-20999	thresholding	_
117-13	21000-21002	is	_
117-14	21003-21004	a	_
117-15	21005-21014	necessary	_
117-16	21015-21019	step	_
117-17	21020-21022	to	_
117-18	21023-21030	extract	_
117-19	21031-21034	the	_
117-20	21035-21046	appropriate	_
117-21	21047-21058	topological	_
117-22	21059-21069	properties	_
117-23	21070-21072	of	_
117-24	21073-21081	networks	_
117-25	21081-21082	.	_

Text=Because graph measures can also be sensitive to threshold value, we have reported our measures across a range of K thresholds (1   ⩽   K   ⩽   5, increments of 1).
118-1	21083-21090	Because	_
118-2	21091-21096	graph	_
118-3	21097-21105	measures	_
118-4	21106-21109	can	_
118-5	21110-21114	also	_
118-6	21115-21117	be	_
118-7	21118-21127	sensitive	_
118-8	21128-21130	to	_
118-9	21131-21140	threshold	_
118-10	21141-21146	value	_
118-11	21146-21147	,	_
118-12	21148-21150	we	_
118-13	21151-21155	have	_
118-14	21156-21164	reported	_
118-15	21165-21168	our	_
118-16	21169-21177	measures	_
118-17	21178-21184	across	_
118-18	21185-21186	a	_
118-19	21187-21192	range	_
118-20	21193-21195	of	_
118-21	21196-21197	K	_
118-22	21198-21208	thresholds	_
118-23	21209-21210	(	_
118-24	21210-21211	1	_
118-25	21211-21212	 	_
118-26	21212-21213	⩽	_
118-27	21213-21214	 	_
118-28	21214-21215	K	_
118-29	21215-21216	 	_
118-30	21216-21217	⩽	_
118-31	21217-21218	 	_
118-32	21218-21219	5	_
118-33	21219-21220	,	_
118-34	21221-21231	increments	_
118-35	21232-21234	of	_
118-36	21235-21236	1	_
118-37	21236-21237	)	_
118-38	21237-21238	.	_

Text=Here K represents the percentage (e.g., 1   =   10%) number of edges in each matrix that are maintained following thresholding.
119-1	21239-21243	Here	_
119-2	21244-21245	K	_
119-3	21246-21256	represents	_
119-4	21257-21260	the	_
119-5	21261-21271	percentage	_
119-6	21272-21273	(	_
119-7	21273-21276	e.g	_
119-8	21276-21277	.	_
119-9	21277-21278	,	_
119-10	21279-21280	1	_
119-11	21280-21281	 	_
119-12	21281-21282	=	_
119-13	21282-21283	 	_
119-14	21283-21286	10%	_
119-15	21286-21287	)	_
119-16	21288-21294	number	_
119-17	21295-21297	of	_
119-18	21298-21303	edges	_
119-19	21304-21306	in	_
119-20	21307-21311	each	_
119-21	21312-21318	matrix	_
119-22	21319-21323	that	_
119-23	21324-21327	are	_
119-24	21328-21338	maintained	_
119-25	21339-21348	following	_
119-26	21349-21361	thresholding	_
119-27	21361-21362	.	_

Text=We employed a range of thresholds to represent the lower and upper bound of a small-world system, and that preserve only the strongest functional connections for efficient parallel information processing at a relatively low wiring cost.
120-1	21363-21365	We	_
120-2	21366-21374	employed	_
120-3	21375-21376	a	_
120-4	21377-21382	range	_
120-5	21383-21385	of	_
120-6	21386-21396	thresholds	_
120-7	21397-21399	to	_
120-8	21400-21409	represent	_
120-9	21410-21413	the	_
120-10	21414-21419	lower	_
120-11	21420-21423	and	_
120-12	21424-21429	upper	_
120-13	21430-21435	bound	_
120-14	21436-21438	of	_
120-15	21439-21440	a	_
120-16	21441-21452	small-world	_
120-17	21453-21459	system	_
120-18	21459-21460	,	_
120-19	21461-21464	and	_
120-20	21465-21469	that	_
120-21	21470-21478	preserve	_
120-22	21479-21483	only	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
120-23	21484-21487	the	_
120-24	21488-21497	strongest	_
120-25	21498-21508	functional	_
120-26	21509-21520	connections	_
120-27	21521-21524	for	_
120-28	21525-21534	efficient	_
